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Abstract 
Excessive proliferation and migration of vascular smooth muscle cells (VSMC) are 
closely linked to the development and progression of cardiovascular diseases and 
cancer. The cytoprotective enzyme heme oxygenase-1 (HO-1) has been shown to be 
involved in anti-proliferative and anti-migratory effects in VSMC. Cannabidiol (CBD), 
the major non-psychoactive constituent of Cannabis, has been shown to mediate 
numerous beneficial effects in several pathologic conditions.  
Therefore, this thesis investigates the effect of CBD on the disease-associated 
functions of human umbilical artery smooth muscle cells (HUASMC) and the 
expression of HO-1. Both protein and mRNA expression of HO-1 were significantly 
increased by CBD in a time- and concentration-dependent manner. Although the 
expression of several cannabinoid-activated receptors (CB1R, CB2R, 
G protein-coupled receptor 55, transient receptor potential vanilloid 1) was 
demonstrated in HUASMC, an involvement of these receptors in the CBD-mediated 
HO-1 induction was excluded. Instead, the CBD-mediated increase of HO-1 protein 
was reduced by the glutathione precursor N-acetylcysteine (NAC), indicating the 
involvement of reactive oxygen species (ROS), which was confirmed by flow 
cytometric ROS detection. In addition to the CBD-induced increase of HO-1 
expression, inhibition of growth factor-mediated proliferation and migration of 
HUASMC was observed. Neither the inhibition of HO-1 activity nor the knockdown 
of HO-1 protein reduced the CBD-mediated anti-proliferative and anti-migratory 
effects. In fact, inhibition or knockdown of HO-1 induced apoptosis and amplified 
the CBD-mediated anti-proliferative and anti-migratory effects. Overall, this work 
provides the first evidence of a CBD-mediated induction of HO-1 in VSMC and 
potential protective effects against excessive proliferation and migration of VSMC. 
While these data negate HO-1’s involvement in the CBD-mediated inhibition of 
proliferation and migration, they also support HO-1’s anti-apoptotic function in 
oxidative stress-induced cell fate. 
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Kurzzusammenfassung 
Ein exzessives Proliferations- und Migrationsverhalten von vaskulären glatten 
Muskelzellen (VSMC, engl.: vascular smooth muscle cells) ist eng mit der Entwicklung 
und dem Fortschreiten von Herz-Kreislauf-Erkrankungen und Krebs verknüpft. Das 
zytoprotektive Enzym Hämoxygenase-1 (HO-1) ist nachweislich an anti-proliferativen 
und anti-migrativen Effekten in VSMC beteiligt. Für das wichtigste 
nicht-psychoaktive Cannabinoid des Cannabis, Cannabidiol (CBD), wurden zahlreiche 
potentiell therapeutisch relevante Effekte hinsichtlich verschiedener Erkrankungen 
nachgewiesen. 
Die vorliegende Arbeit untersucht daher die Wirkung von CBD auf die 
krankheitsassoziierten Funktionen humaner glatter Muskelzellen der 
Nabelschnurarterie (HUASMC) sowie auf die Expression der HO-1. Die 
Expressionen von HO-1 Protein und mRNA wurden durch CBD zeit- und 
konzentrationsabhängig signifikant erhöht. Obwohl die Expression mehrerer 
Cannabinoid-aktivierter Rezeptoren (CB1R, CB2R, G-Protein-gekoppelter 
Rezeptor 55, Transient Rezeptorpotential Vanilloid 1) in HUASMC nachgewiesen 
wurde, konnte eine Beteiligung dieser Rezeptoren an der CBD-vermittelten Induktion 
der HO-1 ausgeschlossen werden. Stattdessen wurde der CBD-vermittelte Anstieg des 
HO-1 Proteins durch den Glutathion-Vorläufer N-Acetylcystein (NAC) vermindert, 
was auf die Beteiligung reaktiver Sauerstoffspezies (ROS) hindeutete und durch einen 
durchflusszytometrischen ROS-Nachweis bestätigt wurde. Begleitend zur 
CBD-induzierten Steigerung der HO-1 Expression wurde eine Hemmung der 
Wachstumsfaktor-vermittelten Proliferation und Migration von HUASMC 
beobachtet. Weder eine Hemmung der HO-1 Aktivität noch der Knockdown des 
HO-1 Proteins verminderten die CBD-vermittelten anti-proliferativen und 
anti-migrativen Effekte. Tatsächlich führten beide Ansätze zur Induktion von 
Apoptose und einer Verstärkung der CBD-vermittelten anti-proliferativen und 
anti-migrativen Effekte. Insgesamt liefert diese Arbeit den ersten Hinweis auf eine 
CBD-vermittelte Induktion der HO-1 und mögliche Schutzwirkungen gegen eine 
übermäßige Proliferation und Migration von VSMC. Wenngleich diese Daten eine 
Beteiligung der HO-1 an der CBD-vermittelten Hemmung von Proliferation und 
Migration widerlegen, untermauern sie gleichzeitig die anti-apoptotische Funktion der 
HO-1 unter oxidativen Stressbedingungen. 
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1 Introduction 
1.1 Vascular smooth muscle cells 
1.1.1 Characteristics 
Vascular smooth muscle cells (VSMC) are an essential part of the blood vessel system. 
Arteries, veins and small arterioles consist of three morphologically different layers: 
tunicaa intima, tunica media and tunica externa (Figure 1-1) [1]. The tunica intima 
consists of an extracellular matrix tissue, which is mainly composed of collagen and 
proteoglycans [1]. A single-layered endothelium on the luminal side and the inner 
elastic membrane on the peripheral side surround the tunica intima [1]. The tunica 
externa consists of connective tissue and fibroblasts and enables anchoring in the 
tissue and neuronal innervation of the blood vessel [1]. Smooth muscle cells (SMC) 
are mainly localized in the tunica media and regulate the blood vessel physics [1]. By 
coordinating contraction and dilatation, VSMC control the vascular tone and blood 
pressure of the entire organism [1]. VSMC are not terminally differentiated and have 
the ability to change from a contractile/quiescent phenotype to a 
synthetic/proliferative phenotype in a complex regulated process [2, 3].  
Representing the two endpoints of a spectrum of intermediate VSMC phenotypes in 
vessels, these two phenotypes can be distinguished by morphological parameters and 
protein expression patterns (Figure 1-2) [2, 3]. Contractile VSMC are elongated, 
spindle-shaped cells containing large amounts of contractile filaments [2].  
                                              
a from the Latin: tunica - robe, garb 
Figure 1-1: Schematic cross-section of an arterial blood vessel structure. From the outside to 
the inside (luminal side) the vessel consists of the following layers: tunica externa, tunica media and 
tunica intima. The tunica media is limited luminal and peripheral by the internal and external elastic 
membranes. At the luminal side, the vascular wall is limited by a single-layered endothelium. SMC are 
preferentially found in the tunica media. (Illustration created according to [1]) 
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The proteins used to identify the contractile/quiescent phenotype include especially 
α-smooth muscle actin (α-SMA), smooth muscle-myosin heavy chains (SM-MHC) 
and smoothelin, with the latter two being highly specific for this phenotype [2]. 
During the transition towards the synthetic/proliferative phenotype, the expression 
level of contractile marker proteins gradually decreases while expression levels of 
proteins such as collagen I and SMemb (embryonic form of myosin heavy chain) 
increases [2]. VSMC displaying a more synthetic/proliferative phenotype are therefore 
characterized by an enhanced proliferative and migrative capacity, synthesis of 
extracellular matrix proteins and a pronounced localization in the tunica intima [2]. 
The synthetic/proliferative phenotype can be identified by changes in the ratio of 
specific contractile markers (e. g. h-caldesmon and meta-vinculin) [2]. In terms of 
morphology, VSMC of the synthetic/proliferative phenotype are less elongated and 
show a cobblestone morphology in culture, which is also referred to as epithelioid or 
rhomboid [2]. Ultrastructural investigations on synthetic/proliferative VSMC showed 
an increased amount of cell organelles (e. g. endoplasmic reticulum [ER], Golgi 
complex and ribosomes), all of which are involved in protein synthesis [4]. 
Figure 1-2: Phenotype-dependent characteristics and marker proteins of VSMC. Schematic 
illustration of morphologic and phenotype-dependent functional properties of contractile (left) and 
synthetic (right) VSMC. The changes of some marker proteins during phenotype transition are 
indicated by triangles. α-SMA: α-smooth muscle actin; SM22 α: smooth muscle protein 22 α; 
SM-calponin: smooth muscle-calponin; SM-MHC: smooth muscle-myosin heavy chain; MMP: matrix 
metalloproteinase; SMemb: embryonic smooth muscle-myosin heavy chain (Illustration created 
according to [2, 3]) 
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1.1.2 The physiological importance of the VSMC phenotype transition 
The VSMC within a particular vessel exhibit variations in morphological and 
functional characteristics as well as differences in the expression of marker proteins, 
reflecting the presence of several different phenotypes [5–8]. This array of possible 
phenotypes forms a heterogeneous arrangement with (epi)genetically [9] controlled 
limitations for each SMC subpopulation [2]. The phenotype transition of VSMC is 
particularly important for the establishment of a vascular network in embryogenesis 
[2]. Nevertheless, vascular remodeling and repairs are also required to adapt to 
changes in physiological stress such as pregnancy, movement, or vascular injuries [2]. 
Endothelium-modulated, long-lasting, or chronic mechanical forces, such as 
hydrodynamic shear and tensile stresses, which are intensified by blood flow or blood 
pressure [10], stimulate the remodeling of the vessel wall. In addition, VSMC react 
directly to mechanical stretching mediated by certain transmembrane receptors [10]. 
Besides these physical factors, a number of biochemical factors are involved in the 
transition of the VSMC phenotype. These include extracellular matrix proteins 
[8, 11–13], cytokines [14, 15] and several growth factors such as platelet-derived 
growth factor [PDGF]) [16–24] and fibroblast growth factor (FGF) [2, 3]. 
1.1.3 Pathophysiology of dysregulated VSMC transition 
Despite its physiological role, the dysregulation of phenotype transition, together with 
the abnormal proliferation and migration of VSMC, is closely associated with the 
development and progression of cardiovascular diseases and cancer. 
VSMC in cardiovascular disease 
The World Health Organization (WHO) has once again declared ischemic heart 
diseases and strokes, both acute complications of atherosclerotic vessel 
reconstruction, as leading causes of death worldwide [25]. Atherosclerosis, formerly 
considered a response to endothelial injury, is an inflammatory disease [26]. While 
multifactorial endothelial dysfunction is the underlying cause of this disease, VSMC 
are of great importance for the progression of this process [27, 28]. Well-established 
risk factors include elevated serum cholesterol levels (especially low-density 
lipoprotein [LDL]), reactive oxygen species (ROS, caused e. g. by cigarette smoking), 
hypertension, and diabetes mellitus [27]. The restoration of the endothelial function 
requires compensatory mechanisms that alter its normal properties. Consequently, 
endothelial adhesion and permeability increases, thus changing the endothelium from 
being anti-coagulant to being pro-coagulant [27]. A prolonged inflammatory reaction 
additionally stimulates the proliferation and migration of VSMC and thus promotes 
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the development of an intermediate lesion and the thickening of the vascular wall 
[27, 29]. This process is called intimal hyperplasia [27, 29]. Immigration, proliferation 
and activation of immune cells results in a release of hydrolytic enzymes, cytokines, 
chemokines and growth factors in the inflamed region which leads to further damages 
and potential tissue necrosis [27]. The cyclic repetition of immune cell accumulation, 
proliferation, and migration of VSMC and the formation of fibrous tissue leads to 
further expansion and reorganization of the lesion [27]. The result is an advanced 
complex lesion, a so-called plaque, which is a core of lipid and necrotic tissue that is 
covered by a fibrous cap [27]. When exceeding a certain point, the luminal diameter 
will no longer be maintained by compensatory dilatation of the vessel [27]. The lesion 
then invades the vessel lumen and impairs the blood flow (i. e. stenosis of the vessel) 
[27]. The erosion or acute rupture of an unstable plaque causes occlusion of the vessel 
lumen and thus the acute clinical complications ischemic heart disease and stroke [28]. 
VSMC have an ambivalent role in the process of atherogenesis. Although VSMC 
proliferation and migration initially support the plaque formation, the plaque stability 
is enhanced by VSMC located in the fibrous cap [28]. In addition, therapeutic 
interventions intending to restore the blood flow in stenotic vessels are affected by 
abnormal VSMC proliferation and migration, contributing to the recurrence of vessel 
narrowing, called (in-stent) restenosis [30, 31]. It is noteworthy that apoptosis of 
VSMC correlates with plaque rupture and inflammation in atherosclerosis [28]. 
VSMC in angiogenesis and cancer progression  
The formation of blood and lymph vessels, angiogenesis and lymphangiogenesis, are 
well-balanced and important processes during both embryogenesis and wound healing 
[32]. An imbalance to the benefit of the factors supporting (lymph)angiogenesis 
promotes the malignancy and metastasis of solid tumors through nutrient and oxygen 
supply and the provision of pathways for tumor cell metastasis [32]. 
The "angiogenetic switch" is activated by a variety of factors. Metabolic stress, 
inflammatory reactions and genetic mutations lead to the production and release of 
numerous pro-angiogenic molecules, including the vascular endothelial growth factor 
(VEGF), which is a major factor in the initiation of angiogenesis [33]. In the highly 
complex process of cancer angiogenesis, VSMC and pericytes recruited by PDGF 
contribute to the stabilization and maturation of the emerging tumor vessels [33].  
The abnormal proliferation of VSMC thus correlates with (blood)vessel formation in 
cancer and other non-neoplastic diseases [31, 33]. In order to inhibit the tumor 
growth and the formation of metastases, anti-angiogenic strategies are used as 
(neo-)adjuvant treatments to regular cancer therapies (e. g. surgical removal of primary 
tumors, chemotherapy and irradiation) [34, 35]. These anti-angiogenic approaches 
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mainly interfere with VEGF signaling [34, 35]. However, the efficacy of these 
therapies is limited by cancer-specific reactivity, resistance development, and toxicity 
[34, 35]. Consequently, influencing the predominant disease-associated features of 
VSMC, proliferation and migration, could positively affect the success of clinical 
treatment of cardiovascular disease and cancer. 
1.2 The heme oxygenase system 
The heme oxygenase (HO) system is the key player in cellular heme metabolism and 
homeostasis [36] and has attracted considerable attention in past years in the context 
of vascular diseases [37, 38] and cancer [39]. 
1.2.1 Physiological function and degradation of heme 
Heme is a ubiquitous, iron-containing molecule and acts as a prosthetic groupb of 
metalloproteins, so-called hemoproteins [40, 41]. For example, heme is part of the red 
blood pigment hemoglobin, the iron and oxygen binding protein myoglobin in muscle 
tissue, and various other enzymes such as cytochromes and catalase. The most 
common type of heme is heme b, also known as iron-(Fe-)protoporphyrin IX 
(FePPIX). Although the HO substrate heme is an essential molecule for aerobic 
organisms, it produces some unfavorable, even toxic effects when unbound [40, 42]. 
The release of free heme occurs in severe pathological hemolysis (e. g. in sickle cell 
anemia, malaria and after ischemia/reperfusion [I/R]), tissue damage or in conditions 
with increased hemoprotein degradation (e. g. oxidative stress) [40]. In 1968, 
Tenhunen et al. investigated the process of heme degradation and thereby identified 
its underlying enzymatic nature and HO as the rate-limiting enzyme of this reaction 
(Figure 1-3) [36]. The HO activity catalyzes the oxidative conversion of FePPIX into 
biliverdin IXα, carbon monoxide (CO) and divalent iron ions (Fe2+) [43].  
The HO activity depends on the presence of both molecular oxygen (O2) and the 
phosphorylated form of the reduced coenzyme nicotinamide adenine dinucleotide 
(NADH), NADPH/H+c [36]. In contrast, the reaction product CO inhibits the HO 
activity [36]. Consequently, HO enzymes belong to the class of mixed function 
oxygenasesd and involve the cytochrome P450 (CYP450) enzymes in the mechanism 
                                              
b A prosthetic group (also known as cofactor) is covalently linked to an enzyme (or protein) and is 
necessary for its function.  
c Donor of electrons and protons. Used as a reducing agent in reductive biosynthesis. 
d Enzymes that perform reduction-oxidation reactions in which one oxygen atom of molecular 
oxygen is incorporated into the organic substrate, while the other oxygen atom is reduced and 
combined with hydrogen ions to form water. 
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of heme degradation [36, 43, 44]. Subsequently after its production biliverdin IXα is 
converted to the bile pigment bilirubine IXα by biliverdin reductase, which was 
identified in 1965 [45]. While CO is eliminated by lung exhalation, Fe2+ is bound 
directly to the iron transport molecule ferritin, a ubiquitously expressed protein that 
ensures the storage and controlled release of iron [46]. 
1.2.2 The HO isoenzymes and their characteristics 
So far, two isoenzymes of the HO protein have been identified. In 1986, Maines et al. 
were the first to isolate two constitutive isoforms of HO from microsomal fractions 
of rat liver, which were subsequently designated HO-1 and HO-2 [47]. In 1997, a rat 
brain-derived complementary DNA (cDNA) indicated the presence of a third 
isoform, designated HO-3. This cDNA coded for a hemoprotein that shared 90% 
similarity with HO-2 but exhibited lower enzyme activity [48]. However, further 
analyses failed to amplify HO-3 messenger RNA (mRNA) and to detect HO-3 related 
proteins in Western blot [49]. It was thus assumed that HO-3 related genes in rat were 
processed pseudogenes derived from HO-2 transcripts [49]. Until today, the existence 
of putative HO-3-proteins is not yet completely proven. Investigations regarding the 
isoenzymes HO-1 and HO-2 revealed fundamental differences in the characteristics 
                                              
e From the Latin: ruber - red 
Figure 1-3: Reaction of the enzyme-coupled heme degradation. The heme oxygenase catalyzes 
the oxidative cleavage of the pyrrole rings of the heme molecule (Fe-protoporphyrin IX) at the 
methine bridge (marked as the cleavage site) whereby carbon monoxide (CO) and iron (Fe2+) are 
released. NADPH/H+ is required as a reducing agent for the formation of water. The resulting 
biliverdin IXα is characterized by its greenish color. Under catalysis by cytosolic biliverdin reductase, 
the middle methine group is reduced into a methylene group. The reducing agent used here again is 
NADPH/H+. The resulting red-orange product is bilirubin IXα. 
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of both proteins, especially with respect to their activities [47]. In contrast to HO-2, 
the basal activity of HO-1 is 2–3-fold lower, but can be increased in response to 
various chemicals such as cobalt, cadmium, and hematinf [47]. Differences in protein 
sequence and molecular structure were first indicated by experiments analyzing 
thermolability and antigenic specificity [47] and were later confirmed by sequence 
analysis of the isolated proteins [50] (see suppl. Figure 12-1, page 111). While the 
human HO-1 was identified as a 32 kDa protein [51] consisting of 288 amino acids, 
HO-2 is a 36 kDa protein consisting of 316 amino acids [50, 52]. The amino acid 
sequences of HO-1 and HO-2 share 43% identity and contain a conserved catalytic 
nuclear domain [50], known as the “HO signature” (GenBankTM). This HO signature 
is a 24 amino acid long peptide region with 100% similarity in predicted secondary 
structures of HO-1 and HO-2 of different species [53]. Further analyses confirmed 
that HO-1 could not be a post-transcriptional product of HO-2 [50] and showed that 
both proteins are encoded by different genes [50, 54, 55]. HMOX1, the gene encoding 
HO-1, was localized on chromosome 22q12.3 [54, 55], while the HO-2-encoding 
gene, HMOX2, was mapped to the chromosomic location 16p13.3 [54]. Additionally, 
HO-1 and HO-2 differ in their number of heme regulatory motifs (HRMs), identified 
as a cysteine proline (CP) motif [56]. While human HO-1 lacks CP motifs [50], human 
HO-2 contains two conserved HRMs involving the cysteines Cys265 and Cys282 and 
an additional CP motif at Cys127 [57]. Although important for heme binding, these 
HRMs are not involved in the HO-catalyzed heme degradation [57, 58]. These 
differences also indicate for different physiological roles of HO-1 and HO-2 [59]. In 
fact, a regulatory role of HO-2 with respect to the expression of HO-1 was verified by 
the knockdown of HO-2 [60]. This approach led to activation of the HO-1 gene 
promoter, extended half-life of HO-1 mRNA and increased HO-1 protein levels [60]. 
It was therefore assumed that HO-2 can down-regulate the expression of HO-1 and 
thereby regulates the coordinated expression of HO-1 and HO-2 [60, 61]. 
1.2.3 Mechanism and inducers of HO-1 induction 
Since the discovery of HO-1 inducibility [47], the underlying mechanisms and 
potential inducers of HO-1 expression were subject of several investigations and were 
reviewed in detail in [37, 62, 63]. The expression of HO-1 protein is induced by 
endogenous and exogenous substances that all cause cellular damage and oxidative 
stress. These include for example metalloporphyrins (e. g. heme), heavy metals, lipid 
metabolites, inflammatory cytokines, growth factors, reactive oxygen species (ROS) as 
well as UVA radiation, and hypoxia. Transcription of HMOX1 is regulated by several 
stress responsive transcription factors (TFs) such as members of the heat shock 
                                              
f Hydroxide of heme. 
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factors (HSFs), nuclear factor κB (NF-κB), nuclear factor erythroid 2 (NF-E2) and 
activator protein 1 (AP 1) families [62]. A well-known evolutionary conserved 
mechanism regulating HMOX1 transcription involves the TF nuclear factor 
(erythroid-derived 2)-like 2 (Nrf2, Figure 1-4) [63]. Under conditions of stress, Nrf2 is 
released from its inhibitor protein Kelch-like ECH-associated protein 1 (Keap1), 
which is responsible for the cytosolic sequestration and degradation of Nrf2 under 
normal conditions [63]. In addition, the nuclear heme binding protein BACH1 
negatively regulates the expression of HO-1. BACH1 suppresses the transcription of 
HMOX1 under physiological conditions [61, 64, 65], but is decoupled from the 
HMOX1 promoter under conditions of intracellular stress or increased heme content 
[64]. The transcriptional activity of the HO-1 promoter is additionally regulated by a 
GT-repeat length polymorphism, suggesting a genetically programmed strength in the 
HO-1 response [66].   
Figure 1-4: Nrf2-dependent mechanism of HMOX1 transcription under normal and stress 
conditions. Under normal conditions, the level of released heme (H) is regulated and constantly kept 
low by heme oxygenase-2 (HO-2). Keap1 mediates cytoplasmic ejection of Nrf2. Keap1-bound Nrf2 
is marked for proteasomal degradation by poly-ubiquitination (Ub). BACH1, together with the Maf 
protein, is bound to the MARE/ARE. This blocks the promoter of heme oxygenase-1 (HO-1) and 
thus also transcription of HMOX1. Stress conditions lead to an increased release and accumulation of 
heme molecules or to the formation of reactive oxygen species (ROS). HMOX1 transcription is 
initiated by a combinatory mechanism. First, heme enters the nucleus and displaces the heme-binding 
protein BACH1. Second, ROS disrupt the Nrf2-binding disulfide bridge of Keap1. As a result, Nrf2 
enters the nucleus. After binding to the Maf protein, Nrf2 activates the MARE/ARE and thus 
increases the transcription of Nrf2-regulated genes (e. g. HMOX1). Following translation of the 
HO-1 mRNA, active HO-1 protein in the cytosol contributes to the degradation of the accumulated 
heme. The heme oxygenase products bilirubin and carbon monoxide (CO) lead to an additional 
anti-oxidative effect and attenuate the influence of ROS. ARE: anti-oxidative response element; 
Keap1: Kelch-like ECH-associated protein 1; MARE: Maf-recognition element; Nrf2: 
nuclear  factor  (erythroid-derived 2)-like  2; P: indicates phosphorylation; (Illustration created 
according to [61, 63–65]) 
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Additionally, various protein kinases, including mitogen-activated protein kinases 
(MAPKs), have been shown to be involved in the regulation of HO-1 [67–69]. Due to 
its classification as an apparently constitutive enzyme, there have been only few 
studies regarding possible pharmacological manipulations and potential functions of 
HO-2 (for review see [70]). Indeed, a few reports suggest a selective induction of 
HO-2 by some substances such as calmodulin, menadione, and glutamate [71–73].  
1.2.4 The physiological importance of HO-1 
As mentioned above, various stimuli either originating from or causing cellular stress 
can induce the induction of HO-1. This is considered an evolutionarily conserved 
mechanism of cell protection [63]. The essential importance of HO-1 was emphasized 
by a few reports on human HO-1 deficiency. The very young patients presented 
herein suffered from persistent hemolytic anemia, growth retardation, chronic 
inflammation and iron deposition in organs [74, 75]. The high value of the 
anti-oxidative properties of HO-1 for the vascular and endothelial system was clearly 
demonstrated by the glomerular endothelial detachment following severe endothelial 
cell injury and the presence of atherosclerotic modifications in the aorta of 
HO-1-deficient patients [74, 76]. Transgenic knockout mice with a HO-1 deficiency 
also exhibited a reduced stress resistance, endothelial damage and liver and renal 
cytotoxicity [77].  
The HO substrate heme has been shown to mediate LDL oxidation and endothelial 
injury, both of which are closely associated with atherosclerosis [42, 78, 79]. In 
contrast, HO-1 induction or administration of the HO products CO and bilirubin led 
to anti-oxidative effects in numerous studies on various pathological conditions  
[80–90]. For example, CO restored graft function after transplantation-associated cold 
I/R of the rat heart [91] and protected against hemorrhagic shock and 
reanimation-induced organ injury and systemic inflammation in mice [92]. Likewise, 
HO-1-derived bilirubin mediated protection of endothelial cells against oxidative 
stress in an in vitro model of hyperglycemia/diabetes [93]. The specific regulation of 
HO-1 by different pharmacological approaches is therefore considered a promising 
strategy to protect against a variety of diseases characterized by oxidative stress and 
inflammation, such as atherosclerosis [38, 94].  
Regarding the progression of cardiovascular diseases, overexpression of HO-1, which 
was achieved by administration of plant-derived [14, 15, 17, 21, 23, 95–100] or other 
[19, 24, 101] substances, or via retroviral transfection [18, 95], showed many positive 
effects. Although HO-1 was investigated in numerous studies, there is still a lack of 
information about a possible manipulation of the HO system by cannabinoids, 
especially in VSMC.   
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1.3 Cannabinoids 
1.3.1 Historical and biological background of Cannabis 
Cannabis sativa L.g (hemp) is an annual herbaceous plant belonging to the family of 
Cannabacea [102]. Cannabis has been traditionally used for thousands of years for 
ordinary (e. g. production of textiles and ropes) and medicinal purposes, but also as a 
recreational drug [103–106]. The geographical origin of Cannabis is probably located in 
Central Asia with the first known records of its medicinal uses dating back to about 
2800 B.C. [106]. According to legends, the Chinese “Red Emperor” Shen Nungh 
recommended the medicinal use of Ma (ancient Chinese word for Cannabis) for the 
treatment of gouty arthritis, rheumatism, and malaria in his pharmacological essays. 
He is therefore considered the "Father of Chinese herbal medicine". Artefacts from 
ancient times prove the medicinal and non-medicinal use of Cannabis also in Indian 
and Islamic countries [104, 106]. In 1843, the British physician O’Shaughnessy 
observed positive effects of Cannabis for the treatment of rheumatic complaints, 
spastic and convulsive disorders, tetanus, and cholera in traditional Indian medicine 
[107]. These observations were followed by the use of Cannabis extracts as sedatives, 
hypnotics, analgesics, and anticonvulsants in conventional medicine in the 
English-speaking world [104]. Due to the variability in composition and shelf life, 
opiates and synthetic drugs increasingly replaced Cannabis extracts in the early 20th 
century [104]. Finally, in 1961 the United Nations Single Convention on Narcotic Drugs 
prohibited the use of Cannabis except for scientific purposes.  
The chemical composition of Cannabis is highly complex. To date, the number of 
known ingredients has increased to about 560 compounds of all chemical classes, 
including terpenes, modified sugars, hydrocarbons, steroids, quinones, flavonoids, 
nitrogenous substances and amino acids [105, 106, 108]. A mixture of about 120 
mono- and sesquiterpenoids is responsible for the characteristic scent of the plant 
[106]. In the multitude of compounds, about 100 mono- to tetracyclic C21-(or C22-) 
terpenophenolic molecules form the best known and most specific group of 
substances present in Cannabis sativa [105, 108]. These so-called phytocannabinoids are 
also the most important secondary metabolites of Cannabis [109]. The direct precursor 
of most phytocannabinoids, cannabigerolic acid, is formed in an enzymatically driven 
condensation of a C12 polyketide (olivetolic acid) and a monoterpene unit (geranyl 
pyrophosphate) [106]. The cannabinoid biosynthesis takes place in the glandular 
trichomes of the plant and serves as a potential self-defense mechanism, as 
phytocannabinoids induce apoptosis in plant and insect cells [110]. Among the 
                                              
g Named after Carl von Linné, who first described Cannabis sativa. 
h Also to be found as Chen Nung or Shennong. 
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phytocannabinoids, Δ9-tetrahydrocannabinol (Δ9-THC; in the following abbreviated 
as THC; see chap. 1.3.6, page 17) is the main psychoactive constituent of 
Cannabis sativa. In contrast, cannabidiol (CBD, see chap 1.3.6, page 17) is the most 
important non-psychoactive cannabinoid in the plant [106]. However, the presence of 
phytocannabinoids, cannabimimetic, or cannabinoid-like substances is not limited to 
Cannabis (reviewed in [111]). 
1.3.2 The endocannabinoid system 
The endocannabinoid system (ECS) consists of the cannabinoid receptors (CBRs), 
their endogenous ligands, so-called endocannabinoids, and the proteins that 
contribute to their biosynthesis and inactivation [112]. The ECS is involved in the 
regulation of several physiological functions such as movement, memory and learning, 
cognition, appetite, emesis, pain and immune system modulation [113]. Targeting the 
ECS represents therefore a promising therapeutic approach (reviewed in [114–117]). 
The cannabinoid receptors 
Investigations of the underlying mechanisms of THC’s psychoactivity led to the 
discovery and characterization of the CB1R, which is predominantly present in the 
brain and testis [118–120]. A second receptor, CB2R, was identified and characterized 
in 1993 and shows more peripheral presence with high expressions in immune cells 
[121, 122]. However, further investigations extended these distributional limitations 
and showed that both receptors were expressed, albeit with low frequencies, in 
peripheral tissues such as adrenal glands, heart, lung, prostate, uterus, ovary, testicles, 
bone marrow, thymus and tonsils [122]. Additionally, CB2R was also found in cells of 
the central nervous system (CNS), e. g. in microglia cells [123] and neurons [124–126]. 
Both, CB1R and CB2R, are pertussis toxin-(PTX-)sensitive Gi/0 protein-coupled 
receptors whose signaling mediates inhibition of the adenylate cyclase [127–129]. 
Additionally, signaling of both CB1R and CB2R leads to activation of several MAPKs, 
such as p38 MAPK, c-Jun NH2-terminal kinase (JNK) and extracellular 
signal-regulated kinase (ERK) [130–136]. 
The activation of central CB1R influences the release of neurotransmitters, e. g. 
γ-aminobutyric acid (GABA), dopamine, noradrenaline, 5-hydroxytryptamine, 
glutamate and aspartate, thereby inducing the psychoactive effects of Cannabis  
[137–144]. In contrast to CB2R, CB1R signaling is associated with the modulation of 
several ion channels, including different types of voltage-gated calcium channels  
[137, 138, 141, 145, 146], G protein-coupled inward-rectifier potassium channels (Kir) 
[137, 146] and voltage-gated potassium channels [141, 147].  
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Endocannabinoids and endocannabinoid-like compounds 
Endocannabinoids (eCBs), lipophilic substances that are naturally produced in the 
body, act as ligands of cannabinoid receptors (Figure 1-5). The arachidonic acid 
derivative N-arachidonoyl-ethanolamide (AEA, anandamidei), first isolated from the 
porcine brain in 1992 [148], was identified as a competitive agonist with a THC-like 
affinity for the CB1R receptor [145, 149]. In contrast, AEA was shown to be almost 
inactive at CB2R [150, 151]. In 1995, another eCB, 2-arachidonyl-glycerol (2-AG), was 
isolated from the peripheral tissue of the dog [152] and identified as the agonistic 
ligand of both receptors, the central CB1R and the peripheral CB2R [150, 153].  
In 1993, the two brain-derived unsaturated fatty acid ethanolamides, 
N-homo-γ-linolenyl-ethanolamide and N-7,10,13,16-docosatetraenyl-ethanolamide, 
were identified as CB1R ligands via a centrifugation-based ligand binding assay [154]. 
Since then, the substances N-arachidonoyl-dopamine (NADA) [155, 156], 
O-arachidonoyl-ethanolamine (virodhamine) [157] and 2-arachidonylglyceryl-ether 
(noladin ether, 2-AGE) [158] were additionally characterized as eCBs showing 
different affinities to CB1R and CB2R.  
 
Endocannabinoid-like compounds (ELC, Figure 1-6) are saturated or mono-
unsaturated fatty acids like N-acylethanol-amides (e. g. N-oleyl-ethanolamide [OEA] 
and N-palmitoyl-ethanolamide [PEA]) and 2-monoacylglycerols (e. g. 2-oleoyl-glcerol 
[2-OG], 2-linoleoyl-glycerol [2-LG] and 2-palmitoyl-glycerol [2-PG]). Although ELC 
do not bind to the cannabinoid receptors CB1R and CB2R, they partly use the same 
                                              
i From the Sanskrit: ananda - bliss 
Figure 1-5: Chemical structures of endocannabinoids. 
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enzymes for biosynthesis and degradation as the eCBs, mediate autonomous effects, 
and can amplify the eCB-mediated effects (reviewed in [159]). This ELC-mediated 
enhancement of eCB-mediated effects was named the “entourage effect”, which was 
first described in 1998 [160].  
1.3.3 Synthetic cannabinoid receptor agonists 
The intense research regarding the functionalities of the ECS-components required 
and enabled the production of diverse synthetic cannabinoid receptor ligands 
(Figure 1-7). The AEA analog R(+)-methanandamide (MA) exhibits metabolic 
stability against aminopeptidase hydrolysis and an approximately 4-fold higher affinity 
for CB1R than AEA [161].  
In contrast, JWH-133 (1-deoxy-3-(1',1'-dimethylbutyl)-Δ8-THC), which was 
synthesized and described in 1999 as one component of a series of 15 
1-deoxy-Δ8-THC analoges by John W. Huffman, shows a 200-fold selectivity for 
CB2R over CB1R [162]. Nowadays, the list of JWH-substances, including pyrrole-, 
indole-, and dibenzopyrane-derived compounds, comprises ligands of both, CB1R and 
CB2R, [162–164]. For example, JWH-015 is a CB2R-selective agonist [165].  
Figure 1-6: Chemical structures of endocannabinoid-like compounds. 
 
Figure 1-7: Chemical structures of synthetic cannabinoid receptor agonists. 
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In contrast, WIN-55,212-2, CP55,940 , HU-210 and JWH-018 activate both, CB1R 
and CB2R, thereby showing partially higher potencies than THC [146, 165–167]. 
JWH-018 has recently aroused public and political interest, as it occurred in herbal 
mixtures that were smoked as a "high"-producing recreational drug and resulted in 
some reports of critical side effects [168–171]. 
1.3.4 Synthetic cannabinoid receptor antagonists 
In 1995, the characterization of the first highly selective CB1R-antagonist for studying 
the in vivo functions of the ECS, SR141716A (Rimonabant) [172], was followed by 
investigations regarding a series of CBR-targeting pyrazole compounds (Figure 1-8) 
[173]. Herein, the rimonabant analog AM251 was identified as potent CB1R 
antagonist [173], whereas AM630 (6-iodopravadoline) showed competitive 
antagonism at CB2R [174]. The strategies and therapeutic potential of targeting the 
ECS were reviewed in depth elsewhere [175–177]. 
1.3.5 Other cannabinoid targets 
In addition to CB1R and CB2R, several other molecular targets for cannabinoids have 
been identified [176]. For example the transient receptor potential cation channel 
vanilloid 1 (TRPV1) was identified as a target of AEA [178] and NADA [156]. The 
TRPV1 is a non-selective, ligand-gated cation channel that regulates the influx of 
mono- and divalent cations, in particular Ca2+ ions [179], and is widely distributed 
throughout the body [180]. The best known activators of TRPV1 are capsaicin, the 
irritant compound in hot chili peppers, temperatures above 43 °C and acidic 
conditions (pH < 6) [181]. The activation of TRPV1 leads to a painful, burning 
sensation caused by irritation of sensory neurons and the generation of action 
potentials [182]. Accordingly, TRPV1 has a crucial role in pain perception; its 
dysfunction is involved in various disease states, e. g. chronic pain and diabetes [181]. 
Figure 1-8: Chemical structures of synthetic cannabinoid receptor antagonists. 
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The G protein-coupled receptor 55 (GPR55), which was first characterized in 1999 
[183], was identified as the target of various endogenous, plant and synthetic 
cannabinoids, including AEA, 2-AG, PEA, THC, CP55,940 and WIN55,212-2 [184]. 
The expression of GPR55 was verified in numerous organs, including the adrenal 
glands, the CNS, and the gastrointestinal tract [184]. Cannabinoids also interact with 
other molecular targets, including nuclear peroxisome proliferator-activated receptorsj 
(PPARs), serotonin (5-hydroxytryptamine; 5-HT) receptors, nicotinic acetylcholine 
and ionotropic glutamate receptors, as well as opioid receptors (for review see [176, 
185, 186]). 
1.3.6 CBD and THC in research and conventional medicine 
The differences between CBD and THC 
The first isolation and vague structural description of CBD already occurred in 1940 
[187]. However, the structures of the two main phytocannabinoids, CBD and THC, 
were exactly clarified later by Mechoulam and his colleagues in the early 1960s 
(Figure 1-9) [188, 189]. The psychoactive effects of Cannabis and its components were 
investigated in several human and animal experiments [190–194] and, due to the 
progressive investigation of the ECS, they were attributed to the 
cannabinoid-mediated activation of central CB1R [119, 120]. Further analyses revealed 
that THC acts with high affinities at both receptors (Ki(CB1R) ≈ 40 nM; 
Ki(CB2R) ≈ 40 nM) while CBD, although possessing structural similarities to THC, 
showed only weak affinities (Ki(CB1R) ≈ 4,000 nM; Ki(CB2R) ≈ 2,900 nM)  
[128, 146, 165, 195]. This explains CBD’s non-psychoactive nature. In contrast to 
THC, CBD stimulates the TRPV1 with a similar efficacy as the TRPV1 agonist 
capsaicin [196] and thus mediates an increase of the intracellular Ca2+ level, 
desensitization of TRPV1 against capsaicin and inhibition of AEA uptake and 
hydrolysis [195]. Regarding GPR55, both substances show different activities. While 
THC activates the receptor, CBD has been shown to have an antagonistic effect 
[184]. 
                                              
j Transcription factor of target genes involved in e. g. metabolism and energy homeostasis. 
Figure 1-9: Chemical structures of CBD and THC. 
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Cannabinoid-based drugs in conventional medicine 
In 1981, a synthetic THC analog, Nabilone (international nonproprietary name 
[INN], Cesamet®) was approved for the suppression of chemotherapy-associated 
nausea and vomiting [176, 197]. Pure THC, marketed as Marinol®  
(INN: Dronabinol), was approved as an antiemetic in 1985 and as an appetite 
stimulant in 1992 for the treatment of AIDS-related body weight loss [176, 197]. In 
recent years, the interest of medical research in the ECS and cannabinoids as potential 
pharmacotherapeutic interventions for various indications has been emphasized  
[177, 198, 198–202]. The use of Cannabis-based drugs has been evaluated for 
Tourette’s syndrome and recommended for the treatment of adult patients [203]. This 
is also supported by the findings of a study in which the administration of a 
combination of THC (10 mg/d) and CBD (20 mg/d) led to a rapid improvement of 
treatment-resistant symptoms in a patient with Tourette’s syndrome [204]. Since 2017, 
a German legal reform permits the extraordinary medicinal prescription of Cannabis in 
the form of dried blossoms and extracts for patients with severe diseases  
(§ 31 paragraph 6 SGB V). 
Since CBD lacks psychoactivity, it has emerged as the preferred candidate for 
preclinical research and has shown a favorable safety profile in a number of clinical 
studies [205]. CBD is part of the oro-mucosal spray Sativex® (INN: Nabiximols), 
which is approved for the therapy of treatment-resistant multiple sclerosis- 
(MS-)associated spasticity in 22 countries worldwide, including Germany since 2011 
[206]. Sativex® contains roughly equal amounts of both, THC and CBD: each spray 
(100 µl) delivers a dose of 2.7 mg THC and 2.5 mg CBD (Sativex® package leaflet, 
2015). The spray is additionally approved by Health Canada for the symptomatic 
relief of MS-associated neuropathic pain and as an adjuvant analgesic for 
opioid-resistant pain in cancer patients [176]. The benefits of Sativex® therapy for 
patients with MS have recently been confirmed in further clinical studies [207, 208]. 
According to its analgesic effect, a TRPV1-dependent anti-hyperalgesic effect of CBD 
has been demonstrated in acute inflammation [182, 209]. Positive anti-convulsing 
properties of CBD have been reported for decades [210–215]. This finally led to the 
approval of Epidiolex®, a THC-free CBD extract from Cannabis, by the U.S. Food & 
Drug Administration (FDA) in 2018. Epidiolex® is licensed for the treatment of rare 
seizure disorders (i. e. difficult-to-treat or rare forms of epilepsy such as Dravet 
syndrome, Lennox-Gastaut syndrome). In addition to anxiolytic [216–219] also 
neuroprotective effects [220–223] of CBD were reported. In these contexts, the 
participation of 5-HT receptors in these CBD-mediated effects was identified  
[222, 224]. Recently, several trials confirmed the neuroprotective effects of 
Sativex®-like combinations of phytocannabinoids in animal models and human 
patients with Huntington’s disease [225–227]. CBD further induced the migration and 
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osteoblastic differentiation of mesenchymal stem cells, suggesting a potential role in 
wound healing and degenerative bone diseases [228]. Additionally, anti-oxidant 
properties of CBD have been demonstrated in several studies. For example, CBD 
reduced lipopolysaccharide-induced vasculitis in the mouse brain [229], protected 
against hepatic I/R injury [230] and acute alcohol-induced liver steatosis [231] in 
mouse models, and reduced ER stress in oligodendrocyte progenitor cells [232].  
1.3.7 CBD in cardiovascular disease and cancer 
Potential anti-cancer effects of CBD have been demonstrated by inhibition of cancer 
cell invasion [233–236] and endothelial cell angiogenesis [237], induction of cancer 
cell apoptosis [238], and immune cell-mediated cancer cell lysis [239]. The anti-tumor 
effects of cannabinoids and strategies targeting the ECS in terms of anti-cancer 
approaches have recently been intensely investigated [117, 240]. CBD has also 
indicated useful for mediating positive effects on cardiovascular pathologies, which 
have been investigated in detail elsewhere [241]. For example, CBD attenuated the 
high glucose-induced inflammatory response and barrier disruption in human 
coronary artery endothelial cells, indicating potential benefits against diabetic 
complications and atherosclerosis [242]. The cardioprotective effects of CBD were 
further substantiated in vivo. In a rat model of I/R [243] and a mouse model of 
diabetic cardiomyopathy, CBD attenuated myocardial dysfunction by reducing cardiac 
fibrosis, oxidative/nitrative stress, inflammation and cell death [242].  
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2 Aim of  the thesis 
The aim of this study was to investigate the potential benefit of CBD in terms of 
disease-associated characteristics of VSMC, namely the excessive proliferation and 
migration of these cells. In detail, the possible involvement of cannabinoid-activated 
receptors (CB1R, CB2R, TRPV1, and GPR55) and the role of HO-1 in CBD-mediated 
effects should be further evaluated. Human umbilical artery smooth muscle cells 
(HUASMC) were used as a suitable VSMC type. 
To investigate a potential cannabinoid-mediated modulation of HO-1, analyses of 
protein and mRNA expression were performed. In further investigations, the 
underlying mechanism of the CBD effect on HO-1 should be further defined. 
Chemical inhibitors were used to investigate the involvement of cannabinoid-activated 
receptors at the protein level. The participation of reactive oxygen species (ROS) in 
HO-1 induction was analyzed at the protein level and by flow cytometry using the 
glutathione precursor N-acetylcysteine (NAC). In order to evaluate the influence of 
CBD on VSMC functions, proliferation, migration and viability analyses were 
performed. 
The proliferation rate was quantified using the antibody-based BrdU incorporation 
assay. Additionally, photographic images of cell monolayers were taken to visualize 
these effects. The cell viability was determined by trypan blue exclusion staining and 
flow cytometry. Investigation of cellular migration was carried out using a modified 
Boyden chamber assay, which ended with staining and counting of the migrated cells. 
The role of HO-1 was investigated using both, a chemical inhibitor of HO-1 activity 
and knockdown of HO-1 protein expression via RNA interference. 
The outcomes of these investigations provide the basis for further investigations of 
the effects of CBD and other cannabinoids on VSMC. Furthermore, the results of 
this work may complement the existing findings on the anti-tumor properties of 
cannabidiol, which may partly depend on VSMC functions. This study also 
contributes to further elucidation of the function of HO-1 in VSMC. 
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3 Materials and Methods 
3.1 Materials 
All materials, equipment, and software as well as the recipes of buffers and solutions 
used in the experimental and evaluating parts of this work were accurately listed in 
tabular form and included to the attachment of this thesis (see chap. 12.1, page 103). 
3.2 Methods 
3.2.1 Cultivation of adherent cells 
HUASMC are adherent cells which were maintained in antibiotic-free smooth muscle 
cell growth medium (SMCGM) supplemented with fetal calf serum (FCS; 5% [v/v]), 
epidermal growth factor (EGF; 0.5 ng/ml), basic fibroblast growth factor  
(bFGF; 2 ng/ml) and insulin (5 ng/ml). This medium composition is in the following 
referred to as complete SMCGM (cSMCGM). Cells were routinely cultured in 
cSMCGM in tissue culture flasks with a growth area of 75 cm2 (TC75-flask) under 
standard culture conditions (5% CO2, 37 °C, humidified atmosphere). In some 
experiments, however, cells were cultured in a reduced SMCGM (rSMCGM) that 
contained 2% FCS [v/v] but lacked all other supplements. 
Expansion and subcultivation  
For expansion, one vial of cryopreserved HUASMC was quickly thawed in a 
pre-warmed water bath (37 °C) and the cell suspension was immediately transferred 
into a TC75-flask containing 12 ml of pre-warmed cSMCGM. After 24 h, the medium 
was exchanged by fresh, pre-warmed cSMCGM. Thereby, residues of the 
cryopreservation medium as well as non-adhering, dead cells were removed. Every 
second to third day the spent medium was aspirated and exchanged by fresh 
cSMCGM. Subconfluent monolayers were then harvested for subcultivation. 
Therefore, spent medium was aspirated and cells were carefully washed twice with 
5 ml of pre-warmed Dulbecco’s phosphate buffered saline (DPBS). Then, cells were 
enzymatically detached for 1–3 min with 3 ml of a pre-warmed 1X Trypsin-EDTA 
(TE) solution. The pancreatic enzyme trypsin is a serine protease, which specifically 
cuts proteins after defined amino acid sequences. Hereby, cellular adhesion proteins, 
which anchor cells to surfaces and enable cell-cell-interactions, are degraded and cells 
are released into the tissue culture medium. The progress of cell detachment was 
monitored by light microscopy and inactivated by addition of 7 ml Dulbecco’s 
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modified Eagle’s medium (DMEM) containing 10% FCS. Subsequently, cells were 
counted as described below. Viable cells were seeded in TC75-flasks at a density of 
4,000–7,000 cells/cm2.  
Determination of cell number and viability 
The cell suspension was pelleted by centrifugation (210 x g, 5 min). Subsequently, the 
supernatant was aspirated and the cell pellet was resuspended in at least 1 ml of 
cSMCGM. The samples were analyzed for cell number and viability by trypan blue 
assay in a Luna-IITM automated cell counter. Trypan blue is an azo dye derived from 
ortho-tolidine that enters cells through defective cell membranes. Stained cells are thus 
considered dead. In contrast, viable cells will not stain positive for trypan blue. For 
this analysis, 10 µl of cell suspension were mixed with 10 µl of trypan blue solution. 
The mixture was injected into a counting slide. Cells with a size of 10–30 µm size 
were automatically counted and analyzed for cell viability.  
Cryopreservation 
Cryopreservation facilitates long-term storage of cells. For this purpose, subconfluent 
cell monolayers were detached from TC75-flasks and cell number was analyzed as 
described above. After an additional centrifugation (210 x g, 5 min) the cell pellet was 
resuspended in the cryopreservation medium cryo-SFM with a final density of 
1,000,000 viable cells per ml. Subsequently, aliquots of 1 ml per cryopreservation vial 
were stored in a freezing container at -80 °C overnight. The special freezing container, 
which was filled with pre-cooled (-20 °C) isopropanol, allowed a controlled reduction 
of temperature by 1 °C per minute. On the next day, the vials were transferred into a 
liquid nitrogen tank for long term storage at -196 °C.  
Seeding and stimulation of adherent cells 
Cell culture experiments were performed in cell culture plates of different formats, 
such as 6-well, 12-well, 24-well, and 96-well. Proliferation analyses (see chap. Analysis 
of cell proliferation, page 30) were performed in 96-well format using 5,000 cells/well. 
For analysis of protein expressions (see chap. 3.2.6, page 31) and flow cytometry 
experiments (see chap. 3.2.7, page 34), experiments were conducted in 6-well or 
12-well format using 150,000 cells/well or 60,000 cells/well, respectively. For analysis 
of mRNA expressions (see chap. 0, page 27), 33,000 cells were seeded in 24-well 
format. For seeding of cells into these plates, cells were enzymatically detached as 
described in expansion and subcultivation (page 23). Cell number and viability were 
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analyzed as described in determination of cell number and viability (page 24). The detached 
cells were resuspended in the appropriate volumes of the respective SMCGM, 
transferred to the desired wells and allowed to adhere for 24 h in a humidified 
atmosphere (37 °C, 5% CO2). On the next day, cells were examined for confluence 
and viability using light microscopy prior to stimulation with test substances. Then, 
supernatant medium was aspirated and exchanged by fresh, pre-warmed cell culture 
medium. A 1-h pre-incubation was performed in co-incubation experiments using 
N-acetylcysteine (NAC, glutathione precursor, see suppl. Figure 12-2, page 112), 
tin protoporphyrin IX (SnPPIX, inhibitor of HO-1 activity), or substances targeting 
CB1R (AM251), CB2R (AM630), TRPV1 (capsazepine) and GPR55 (O-1918, O-1602) 
respectively. The efficiency of SnPPIX in inhibiting HO-1 activity was explained by its 
competitive antagonism, resulting from a blockade of the heme binding site of HO-1 
[244] and was further proven by bilirubin formation assays in several studies  
[244–246]. The receptor antagonists and O-1602 were used at 1 µM, a concentration 
that has been shown to sufficiently regulate the corresponding receptor activity  
[184, 228, 233, 247]. All incubations were performed in cSMCGM, with the exception 
of experiments using treatment with recombinant human PDGF-BB (hPDGF-BB, in 
the following abbreviated as PDGF). In these experiments, cells were seeded and 
stimulated in rSMCGM (without supplements, 2% FCS). Most test substances were 
dissolved in dimethyl sulfoxide (DMSO) or in ethanol and further diluted in 
cSMCGM or rSMCGM. Final concentrations in incubates were DMSO, 0.01% (v/v) 
(for AM251, AM630, capsazepine, O-1602 and O-1918); ethanol, 0.033% (v/v) (for 
CBD and THC) and 0.1% (v/v) (for JWH-133 and MA). Vehicle for SnPPIX in 
incubates was cSMCGM containing 0.04% (v/v) sodium hydroxide solution  
(NaOH, 1 M). For NAC, vehicle in incubates was cSMCGM containing 0.6% (v/v) 
DPBS. Vehicle for PDGF in incubates was rSMCGM containing 0.02% (v/v) 0.1 M 
acetic acid/0.1% bovine serum albumin. 
3.2.2 Knockdown experiments using RNA interference 
Principle of RNA interference 
RNAs are polynucleotide chains bearing important roles in coding, decoding, 
regulation, and expression of genes. Protein expression is a result of gene 
transcription, in which the mRNAs produced are subsequently translated into 
proteins. RNA interference, mediated by small interfering RNAs (siRNAs), is a 
naturally occurring mechanism of eukaryotic cells leading to a specific switch-off of 
genes by disruption of the mRNA translation [248]. SiRNAs are double-stranded 
RNA molecules of 20–25 base pairs in length that interfere with the translation of the 
mRNA exposing the complementary nucleotide sequence. As a result, the targeted 
26 Materials and Methods 
 
mRNA is degraded, thus diminishing the translation of the respective protein. The 
mechanisms of RNA interference are illustrated and explained in more detail in 
Figure 3-1. 
Transfection procedure 
Knockdown of HO-1 protein expression was performed using LipofectamineTM 
RNAiMAX transfection reagent in a reversed procedure according to the 
manufacturer’s instructions. In contrast to general transfection procedures, this 
method enables the enhancement of transfection efficiency and tolerability by 
transfecting cells in suspension. For one well of a 6-well plate, transfection complexes 
were generated by mixing 45 pmol siRNA with 5 µl LipofectamineTM RNAiMAX in 
Opti-MEM to a final volume of 500 µl. The solutions were mixed thoroughly and 
incubated for 20–30 min at room temperature to form transfection complexes.  
Then, HUASMC at a density of 150,000 cells/2.5 ml SMCGM were seeded in 6-wells 
already containing the generated transfection complexes. Control cells were 
transfected with the same amount of a non-targeting siRNA (NON). Experimental 
settings were adapted for biochemical and flow cytometry assays, which were 
conducted in other well plate formats. The final concentration of siRNA was 15 nM. 
After 24 h, the transfection medium was replaced with fresh medium and cells were 
used for experiments.   
Figure 3-1: Scheme of RNA interference. After 
passing the cell membrane (1), the dsRNA molecules are 
truncated by Dicer (2). The siRNA molecules generated 
in this way, bind to the RNA-induced silencing complex 
(RISC, 3) which enzymatically separates sense (blue) and 
anti-sense strand (red, 4). The target mRNA is released 
from the nucleus and binds complementary to the 
anti-sense strand of the siRNA (5). The nuclease subunit 
of RISC splices the mRNA (5). Both, siRNA’s sense 
strand and the spliced mRNA fragments are then 
degraded (6). (Illustration created according to [248]). 
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3.2.3 Analysis of mRNA expression via qRT-PCR 
Historical and functional background of qRT-PCR method 
The combination of reverse transcription (RT), polymerase chain reaction (PCR), and 
quantification (q) is termed qRT-PCR. The PCR was developed by the biochemist 
Kary B. Mullis and his colleagues at the end of the 1980s [249, 250]. This method 
enables the in vitro amplification of DNA using a DNA polymerase (for detailed 
information please refer to Figure 3-2) [249, 250]. The method’s name was derived 
from the chain reaction in which the products of the previous cycles are exponentially 
duplicated in the subsequent cycles. The investigation of gene expression patterns 
using RNA samples is enabled by the use of a RNA-dependent polymerase (RDP), 
also known as reverse transcriptase (RT). This enzyme naturally occurs in retroviruses 
(e. g. HIV) and DNA viruses (e. g. the hepatitis B virus) and transcribes RNA into 
DNA. The synthetic production of cDNA from natural RNA by use of a RDP from 
avian myeloblastosis virus (AMV) was first reported in 1971 [251]. One-step-RT-PCR, 
as used in the present study, was first described in 1990 [252]. The method utilizes the 
heat-stable Taq-polymerase, which derives from the bacterium Thermus aquaticus. 
Although being a DNA-polymerase, the Taq-polymerase exhibits RDP-activity. This 
approach reduced response time and improved accuracy of the reaction [252]. 
Application of fluorescence-labelled probes enables the quantification of the amplified 
DNA in real time. It is therefore referred to as real-time or quantitative PCR (qPCR). 
In this process, the fluorescence increases in proportion to the number of PCR 
products. This project used so-called FAM probes. These probes are coupled to a 
Figure 3-2: Schematic representation of the 
qRT-PCR process. Taq-polymerase (Taq) recognizes 
the target specific primers (green) that bind to the 
template mRNA (red). Taq, by its RDP-activity, 
synthesizes a cDNA (blue), thereby constructing an 
mRNA:cDNA hybrid. This hybrid, and later the 
double-stranded DNA fragments, is separated by heat. 
This is called denaturation. Probes and 
sequence-specific primers hybridize at approx. 50–
68 °C. The optimum temperature is slightly below the 
melting temperature of the primer, which depends on 
its length. Extension of primer-DNA (elongation) by 
Taq occurs at approx. 72 °C. In this process, the 
attached probe is gradually replaced by 
newly-synthesized DNA. The separation of the 
reporter fluorophore (R, e. g. FAM) and the quencher 
(Q) eliminates the quencher’s inhibitory effect thus 
enabling the detection of the fluorescence signal. After 
elongation, the next PCR cycle starts with the 
denaturation of the synthesized products.  
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quencher at the 3' end and to the reporter fluorescent dye FAM 
(6-carboxyfluorescein) at the 5' end. The 5'-3'-exonuclease activity of the Taq-
polymerase separates the reporter fluorophores from the probe during DNA 
synthesis. The increasing distance between quencher and fluorophores enables the 
measurement of reporter fluorescence. This occurs at the end of each elongation 
cycle.  
Sample preparation 
For quantification of mRNA expressions, 33,000 cells were seeded in 24-well format 
and treated as described above (see chap. 3.2.1, page 24). After exposure to test 
substances or vehicles, the total RNA was isolated using the RNeasy Mini kit 
according to the manufacturer’s instructions. Briefly, the supernatant was removed 
and cells were covered with 350 µl of RLT lysis buffer. If necessary, the plates were 
sealed and stored at -80 °C until further processing. Thawed lysates were covered with 
350 µl of 70 % ethanol. The mixture was transferred into centrifugation columns and 
centrifuged at 800 x g for 20 s. The fluid has been discarded. The columns were 
washed initially with 500 µl of the RW1 buffer and subsequently two times with 500 µl 
of RPE buffer. The last washing step was followed by centrifugation at 8,000 x g for 
2 min. The liquid flow was discarded and the column was centrifuged dry at 
14,000 x g. The RNA was eluted with 30 µl of RNase-free water and centrifugation at 
8,000 x g for 1 min. The RNA was collected in a RNase-free reaction vial and stored 
at -80 °C until further analysis. Expression levels of target mRNAs were determined 
by qRT-PCR using the TaqMan® RNA-to-CTTM 1-Step kit. Primers and probes for 
human β-actin, HO-1 and HO-2 were TaqMan® gene expression assays. All 
experiments were performed according to the manufacturer’s instructions.  
Briefly, a RNA template-free master mix was prepared as listed in Table 3-1. 
Then, 5 µl of RNA template were transferred to a MicroAmpTM reaction plate prior to 
the addition of 15 µl master mix. All components were light-protected and kept on ice 
for the time of preparation. The reaction plate was sealed with optical adhesion film 
before starting the procedure.  
Table 3-1: Composition of qRT-PCR master mix 
Component Volume for one reaction 
TaqMan® RT-PCR mix (2X) 10.0 µl 
TaqMan® gene expression assay (20X) 1.0 µl 
TaqMan® RT enzyme mix (40X) 0.5 µl 
RNase-free water 3.5 µl 
Total volume 15.0 µl 
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The qRT-PCR, including 40 cycles of PCR, was run using the temperature protocol 
depicted in Figure 3-3. The levels of mRNA expression were analyzed by comparison 
of threshold cycle (Ct) valuesk. HO-1 and HO-2 mRNA levels were normalized to 
β-actin and samples were compared to appropriate vehicle controls. 
3.2.4 Analysis of cell migration 
Principle of migration experiments 
Migration is the active locomotion of cells resulting in a change of place. The term 
migration includes the undirected spontaneous (random) migration, the directed 
chemotactic movement and changes in chemokinesis. Using a modified Boyden 
chamber assay cellular motility was monitored as migration through Falcon® cell 
culture inserts (8 µm pore size) towards the chemoattractant PDGF. 
Procedure of migration experiments 
In order to investigate the role of HO-1 in the migration of HUASMC, two different 
experimental settings were used. First, cells seeded in rSMCGM were subjected to 
treatment with the HO-1 activity inhibitor SnPPIX and test substances as stated 
above (see chap. 3.2.1, page 24). After incubation, cells were counted and viable 
HUASMC (50,000 cells/0.5 ml rSMCGM) were seeded in Falcon® cell culture inserts. 
Migration was initiated subsequently. Second, after reversed transfection in rSMCGM 
(see chap. 3.2.2, page 26), viable HUASMC (30,000 cells/0.5 ml rSMCGM) were 
seeded in Falcon® cell culture inserts and incubated (37 °C, 5% CO2) with CBD 
(6 µM and 10 µM) or appropriate vehicle for 60 min before initiation of migration. In 
both setups, migration was initiated by addition of 500 µl rSMCGM containing 
                                              
k The Ct value is a theoretical quantity that describes the beginning of the exponential growth of a 
curve. In this method, the Ct value describes the part of the curve in which the fluorescence for the 
first time increases exponentially above the background value. 
Figure 3-3: Scheme of the qRT-PCR 
temperature  profile. Reverse trans-
cription proceeded at 48 °C for 15 min. The 
Taq-polymerase was thermally activated at 
95 °C for 10 min. This was followed by 40 
PCR cycles. The DNA was denatured at 
95 °C for 10 s. Hybridization of primers 
occurred after cooling to 60 °C. After 1 min 
the temperature was increased to 95 °C. 
Elongation occurred during the 
temperature increase. 
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PDGF (20 ng/ml) or vehicle to the companion plate. Cells were further incubated 
(37 °C, 5% CO2) for 6 h. Then, supernatant medium was aspirated and non-migrated 
cells on the upper surface of the insert were removed with a cotton swab. Afterwards, 
the insert was carefully washed with DPBS. Cells on the lower surface of the inserts 
were fixed and stained with Diff-Quick staining according to the manufacturer’s 
instructions. Briefly, the prepared inserts were successively dipped into fixation 
solution, staining solution I and staining solution II. The inserts were immersed for up 
to 10 s in each solution. Between the different steps, adhering excess of solutions was 
wiped off on a paper towel. Afterwards, fixed and stained inserts were washed in 
deionized water to remove excess dye. After complete drying, inserts were 
photographed at 10X magnification using a digital microscope camera. Five randomly 
selected fields per insert were counted. 
3.2.5 Analysis of cell proliferation 
Principle of proliferation assay 
Bromodeoxyuridine (BrdU) is a synthetic nucleoside that is chemically analog to 
thymidine and deoxyuridine, respectively. BrdU is generated by connection of 
deoxyribose and the nucleobase 5-bromouracil and is used in the diagnostic labelling 
of proliferating cells in vital tissues [253]. BrdU is incorporated by cells and 
subsequently, its phosphorylated form is integrated into newly synthesized DNA 
thereby substituting the nucleotide deoxythymidine triphosphate (dTTP). Thus, BrdU 
labelling of cells directly correlates to the rate of DNA synthesis during the synthesis-
(S-)phase of the cell cycle. Antibodies directed against BrdU are then used to detect 
the incorporated chemical, indicating actively replicating cells. Antibody labelling 
requires denaturation of DNA and opening of cell membranes, both realized by 
exposing the cells to acid. 
Procedure of the proliferation assay 
The impact of test substances on proliferation of HUASMC was quantified using 
BrdU Cell Proliferation enzyme-linked immunosorbent assay kit according to the 
manufacturer’s instructions. Briefly, 5,000 cells were seeded into 96-well format and 
allowed to grow for 24 h. Then, the medium was refreshed and cells were challenged 
to test substances or vehicles for the indicated times. 1X BrdU reagent was added 
6-24 h prior to analysis. After incubation, the medium was removed and the cells were 
covered with fixing solution and incubated for at least 30 min at room temperature. 
Then, the samples were washed three times with 1X wash buffer and incubated with 
pre-diluted anti-BrdU detection antibody for 1 h at room temperature.   
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Afterwards, the samples were washed three times with 1X wash buffer and incubated 
with HRP-conjugated secondary detection antibody (30 min, room temperature). 
Then, the samples were washed three times with 1X wash buffer plus an additional 
washing using distilled water. Then, samples were incubated with substrate solution 
for a maximum of 30 min light-protected. The stop solution was added at the end of 
the incubation period or when the samples turned blue. The absorption was measured 
at 450/550 nm using a plate reader. Cells that did not receive BrdU reagent served as 
blank. Each experiment consisted of four repeats per sample. 
3.2.6 Protein expression analysis 
The evaluation of the influences of the test substances on cellular protein expression 
patterns was carried out using the Western blot technique. For this purpose, cellular 
proteins were isolated, separated and detected to ensure a specific and quantitative 
analysis. 
Isolation of cellular proteins 
Whole cell culture lysates were prepared by combining floating and adherent cells. 
Briefly, the supernatant containing floating cells was collected and adherent cells were 
washed with pre-warmed DPBS before being detached using 1X TE. Trypsin activity 
was inhibited by addition of 10% DMEM and cells were rinsed off the wells and 
combined with the collected floating cells. After centrifugation (800 x g, 5 min), the 
cell pellet was resuspended in 50 µl sample buffer. Cells were then lysed by sonication, 
heated for 5 min at 95 °C and centrifuged at 20,000 x g for 5 min at 4 °C. Supernatants 
were stored at -20 °C until further analysis. 
Principle and procedure of protein concentration analysis 
The protein concentrations of cellular lysates were determined using the Pierce® 
bicinchoninic acid (BCA) protein assay kit according to the manufacturer’s protocol. 
This assay relies on two distinct reactions (Figure 3-4) [254]. First, peptide bonds in 
the proteins reduce Cu2+ ions from copper (II) sulfate to Cu+ in a temperature-
dependent reaction and proportional to the amount of protein present in the sample. 
In a ratio of 1:2 Cu+ ions and BCA form a purple-colored complex with a maximum 
absorption at approx. 570 nm. Briefly, 5 µl of lysate were mixed with aqua ad 
injectabilia yielding a final dilution of 1:10. Then, 10 µl of the diluted lysate were 
mixed with 200 µl of working solution (50:1-mixture of reagent A and reagent B as 
provided in the kit) after transfer into 96-wells.  
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Protein concentrations of samples were quantified under consideration of the sample 
dilution using the calibration function of a standard curve from 0–1 mg/ml bovine 
serum albumin. Standards and samples were analyzed in duplicates and triplicates, 
respectively. After incubation (37 °C, 30 min), absorbance was measured at 570 nm 
using a plate reader.  
Protein separation 
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE), invented by 
Ulrich K. Laemmli, enables the separation of proteins in an electrical field according 
to their molecular weight [255]. The separating matrix used in this electrophoresis was 
a discontinuous gel based on poly acrylamide. By use of the anionic detergent SDS, 
the charge of the proteins is covered resulting in negatively charged SDS-protein 
complexes. Proteins and SDS bind in a ratio of 1.4 g SDS/g protein [256]. Both, 
negative SDS charge (causes repulsion) and heating of the samples, lead to the 
denaturation (i. e. linearisation) of the proteins. This procedure allows protein 
separation according to protein length, which is proportional to the molecular weight. 
Large proteins have a higher retention than small proteins, which leads to different 
migration patterns.  
SDS-PAGE was conducted using either Bio-Rad Mini-PROTEAN® Tetra Cell 
System or SE 250 Mini-Vertical Unit. For electrophoresis, gels with 10% or 12% 
acrylamide content and 1 mm or 1.5 mm thickness were used to separate samples 
containing 50 µg of total protein. Samples were adjusted to equal protein 
concentration and sample volumes by mixing with aqua ad injectabilia. Permanent 
breakdown of disulfide bonds was ensured by addition of 5% [v/v] 
β-mercaptoethanol to each sample. Samples were additionally supplemented with  
1–2 µl bromophenol blue to visualize the migration front. Then, protein samples were 
carefully transferred into the pockets of the gel using a microliter syringe.   
Figure 3-4: Chemical reaction of the BCA protein assay. Reaction equation according to [254]. 
See text for details. Cu2+: divalent copper ion; OH-: hydroxide ion; Cu+: monovalent copper ion; 
BCA: bicinchoninic acid 
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For the approximation of the protein size, a prestained SDS-PAGE standard was run 
simultaneously. Gels were run in 1X electrophoresis buffer at 15 mA/gel (stacking 
gel) and 25 mA/gel (separation gel), respectively. Electrophoresis was stopped before 
the migration front reached the end of the gel. 
Western blot protein transfer 
Immediately after electrophoretic separation, proteins were transferred onto a 
nitrocellulose membrane by Western blot technique using a semi-dry transfer system. 
Therefore, extra-thick blotting paper and nitrocellulose membrane were cut to the size 
of the gel and pre-incubated in transfer buffer for 5–30 min. Excess of buffer solution 
was removed from blotting papers prior to transfer preparation. Then, a blotting 
sandwich was assembled by stacking following layers from bottom to top: blotting 
paper - nitrocellulose membrane - gel - blotting paper. Air bubbles were removed and 
the blotting sandwich was compressed by carefully rolling over every layer using a 
glass tube. Transfer was run for 70 min at 41 mW/cm2, 2.73 mA/cm2 and 15 V 
(constant). 
Immunologic detection of proteins (chemiluminescence)  
After the transfer was completed, membranes were put into 50 ml centrifuge tubes to 
remove residual transfer buffer by washing with TRIS-buffered saline/Tween®20 
(TBS-T). All washing and incubation steps were performed on a roller mixer at 
30 rotations per minute. Blocking of free nitrocellulose binding sites was ensured by 
incubation for 1 h in blocking solution (BS). Then, membranes were incubated with 
specific primary antibodies at 4 °C overnight. Afterwards, membranes were washed 
with TBS-T and probed with appropriate horseradish peroxidase-linked secondary 
antibodies. All antibody dilutions used here are listed in Table 3-2. Antibody binding 
was visualized by enhanced chemiluminescence (ECL) reaction (see suppl. 
Figure 12-3, page 113) and quantified by densitometric analysis using Quantity  
One 1-D analysis software. Therefore, membranes were placed in an unlighted 
Bio-Rad universal hood and covered with 2 ml of ECL detection solution. Emission 
of light was detected in intervals for up to 300 s (e. g. for HO-1, HO-2) or a 
maximum of 60 s (for β-actin) with starting times dependent on the signal strength. 
Images that did not show overexposed signals were used for quantification. After 
analysis, membranes were prepared for reprobing or storage as described below. 
Expressions of proteins were normalized to β-actin and compared to the appropriate 
vehicle controls. 
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Stripping and storage of membranes 
The removal or inactivation of primary and secondary antibodies from a membrane is 
termed “stripping”. This operation is used in order to investigate more than one 
protein on the same blot. Therefore, the membranes were incubated twice with 5 ml 
of 1X stripping buffer for 15 minutes. Then, the membranes were washed three times 
with TBS-T. Subsequently, the membranes were incubated in 3–5 ml of BS and 
reprobed with another primary antibody. If no reprobing was required, membranes 
were stripped and washed gradually with TBS-T and deionized water, respectively. 
Then, membranes were air dried on paper towels and stored in transparent pockets  
at 4 °C.  
3.2.7 Flow cytometry analyses 
Operating principle of flow cytometry  
The flow cytometry analysis is based on the detection of optical signals emitted by 
single cells after passing a laser beam (for detailed illustrations refer to 
suppl. Figure 12-4, page 114). The sheath fluid hydrodynamically focuses the cell 
suspension. This divides the cell population into single cells, which are then directed 
into the measuring cuvette (i. e. flow cell). Herein, the single cells pass a laser beam 
and thus scatter the light. The forward scatter, which is measured along the path of 
the laser, allows the discrimination of cells by size. The side scatter, which is measured 
at a 90-degree angle relative to the laser, provides information about the internal 
complexity (i. e. granularity) of a cell. Measurement of both light scatters in 
conjunction allows simple cellular differentiation within a heterogeneous cell 
Table 3-2: Antibody dilutions used for immunologic detection. 
Primary 
antibody 
Dilution in  
5% BS 
Secondary 
antibody 
Dilution in 
1% BS 
HO-1 1:1,000 
anti-rabbit IgG 1:1,000 
HO-2 1:1,000 
TRPV1 1:500 
GPR55 1:500 
CB1R 1:200 
anti-mouse IgG 1:1,000 CB2R 1:200 
β-actin 1:10,000 
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population. Additionally, the measurement of emitted fluorescence signals, induced by 
labelling with fluorescent probes, allows further distinctions by detection of e. g. cell 
surface markers (such as the cluster of differentiation [CD]), membrane integrity  
(a parameter for cell viability), DNA content and others.  
Detection of oxidative stress using CellROX
TM
 green staining 
Analysis of oxidative stress in HUASMC was performed using the CellROXTM green 
flow cytometry assay kit according to the manufacturer’s instructions.  
The CellROXTM green reagent is a cell-permeable probe that, when oxidized in 
presence of ROS, binds to DNA and exhibits a strong fluorogenic signal with 
absorption/emission maxima of 508/525 nm. Co-staining with SYTOXTM red dead 
cell stain allows distinction between oxidative stressed, non-stressed and dead cells. 
Briefly, HUASMC were seeded in 12-well plates and allowed to adhere for 24 h. 
Then, medium was refreshed and cells were pre-incubated with NAC (0.5–3 mM) or 
vehicle for 1 h. Cells were then co-incubated with CBD (6 µM, 10 µM) for 3 h before 
addition of CellROXTM green reagent (500 nM). After 1 h, floating cells were collected 
and combined with the adherent cells that were harvested by detachment with 
accutase solution according to the manufacturer’s instructions. Cells were pelleted by 
centrifugation (200 x g, 5 min) and carefully resuspended in 200 µl cSMCGM. Finally, 
SYTOXTM red dead cell stain (5 nM) was added and cells were incubated in the dark 
for 15 min at room temperature. Subsequently, 10,000 cells per sample were analyzed 
with an AccuriC6TM flow cytometer. Appropriate gating of cell populations and 
compensation was ensured by analysis of unstained and single-stained cells, 
respectively. HUASMC that were treated with the ROS inducer tert-butyl 
hydroperoxide (TBHP, 250 µM) for 1 h prior to sample preparation served as a 
positive control. Negative control cells were pre-incubated with NAC (0.5 mM) prior 
to stimulation with TBHP.  
Detection of apoptosis by Annexin V/propidium iodide staining 
Detection of apoptosis was accomplished by flow cytometry using Fluorescein 
isothiocyanate-(FITC-)Annexin V (AV) apoptosis detection kit I according to the 
manufacturer’s instructions. During apoptosis, cells undergo certain morphological 
changes such as loss of plasma membrane asymmetry, cell shrinkage and 
condensation of cytoplasm and nucleus. AV is a phospholipid-binding protein with 
high affinity for phosphatidylserine, which is exposed on the outer side of apoptotic 
but not viable cells. Both, progression of apoptosis and necrosis lead to loss of 
membrane integrity of cells. Therefore, co-staining with propidium iodide (PI), a 
membrane-impermeable dye, allows distinction between early- and late-apoptotic 
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cells. Cells that are considered viable are negative for both FITC-AV and PI; cells in 
early apoptosis are positive for FITC-AV but negative for PI. However, due to the 
loss of membrane integrity and binding of both FITC-AV and PI, there is no exact 
differentiation between late-apoptotic and necrotic cell populations in this assay. 
Briefly, HUASMC were seeded in 12-well plates and allowed to adhere for 24 h. After 
incubation with test substances, floating cells were collected and combined with the 
adherent cells that were harvested by detachment with accutase solution according to 
the manufacturer’s instructions. Cells were pelleted by centrifugation (400 x g, 4 °C, 
and 5 min) and were then washed twice in 500 µl DPBS. Afterwards, cells were 
carefully resuspended in 200 µl 1X AV-binding buffer and incubated with 2 µl 
FITC-AV and 1 µl PI solution. Following 15 min of incubation in the dark, 
10,000 cells per sample were analyzed with an AccuriC6TM flow cytometer. 
Appropriate gating of cell populations and compensation was ensured by analysis of 
unstained and single-stained cells, respectively. HUASMC that were fixed with ethanol 
prior to incubation with AV and PI served as a staining control. 
3.2.8 Statistics 
Measurement values of cell proliferation assay were analyzed for statistical outliers in 
each experiment using Nalimov test. Statistical analysis was performed using 
GraphPad Prism 6.01. One-way ANOVA plus Dunnett post hoc test was used for 
comparison of samples to vehicle control. Comparison among selected groups was 
carried out by Student’s two-tailed t test (for kinetics) or with one-way ANOVA plus 
Šidák post hoc test. All values are presented as mean ± standard error of the mean 
(SEM). A p value P < 0.05 was considered significant. 
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4 Results 
4.1 Effects of cannabinoids on HO protein expression in HUASMC 
A first experimental approach aimed to investigate the potential of four different 
cannabinoids, the phytocannabinoids CBD and THC (CB1R/CB2R agonist) as well as 
the synthetic cannabinoids R(+)-methanandamide (MA, CB1R agonist) and JWH-133 
(CB2R agonist), to influence HO-1 and HO-2 protein expression in HUASMC. 
Therefore, the cells were incubated for 24 h with increasing concentrations  
(0.1–10 µM) of the substances or respective vehicles followed by Western blot 
analysis (Figure 4-1). 
 
Figure 4-1: Effects of cannabinoids on HO-1 and HO-2 protein expression in HUASMC.  
Cells were incubated for 24 h with CBD (A), THC (B), R(+)-methanandamide (MA) (C) or JWH-133 
at the indicated concentrations. Following incubation, cells were harvested and lysates were analyzed 
for protein expression of HO-1 and HO-2 by Western blot. Protein expression values were 
normalized to β-actin. Percent control represents comparison with the corresponding vehicle-treated, 
time-matched group (set as 100%). Values are means ± SEM of n = 4 (A, HO-1), n = 5 (A, HO-2) or 
n = 3 (B, C, D) experiments. *P < 0.05 vs. time-matched vehicle control; one-way ANOVA plus 
Dunnett post hoc test. 
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HO-1 protein expression was significantly increased in a concentration-dependent 
manner by both CBD (Figure 4-1A) and THC (Figure 4-1B). The CBD-mediated 
induction of HO-1 was significant at concentrations of 6 µM and 10 µM CBD, 
resulting in 2.7-fold and 5.4-fold increases of HO-1 protein, respectively 
(Figure 4-1A). Similarly, HO-1 protein expression was strongly increased at 6 µM 
THC (3.9-fold) (Figure 4-1B). The THC-mediated induction of HO-1 protein became 
significant at 10 µM, resulting in a 5.8-fold increase (Figure 4-1B). Conversely, neither 
R(+)-methanandamide (Figure 4-1C) nor JWH-133 (Figure 4-1D) led to a significant 
enhancement of HO-1 protein expression in the cells. Finally, HO-2 protein 
expression of HUASMC was not altered after incubation with increasing 
concentrations of any cannabinoid tested (Figure 4-1A–D).  
CBD, due to its lack of psychoactivity and the potent induction of HO-1 shown in 
these experiments, displays an interesting candidate substance for therapeutic 
applications. CBD was therefore selected for further investigations in this study. 
4.2 Characteristics of CBD-mediated HO-1 induction 
Additional analyses targeted to characterize the CBD-mediated induction of HO-1 in 
HUASMC (Figure 4-2). First, investigations regarding an involvement of mRNA 
expression were performed following incubation with increasing concentrations  
(0.1–10 µM) of CBD or the corresponding vehicle (Figure 4-2A).  
After a 24-h incubation with CBD, HO-1 mRNA expression was strongly enhanced 
at 6 µM (4.8-fold) and became significant after incubation with 10 µM CBD which 
resulted in an 8.1-fold increase (Figure 4-2A). In consistence to the results of the 
protein expression analysis (Figure 4-1A, page 37), there was no increase of HO-2 
mRNA expression in HUASMC following incubation with CBD at any concentration 
tested (Figure 4-2A). Next, kinetic studies were performed to investigate possible 
time-dependent effects of CBD on HO-1 mRNA and protein expression 
(Figure 4-2B–C). Therefore, cells were incubated for 6 h, 24 h or 48 h with 6 µM 
CBD, a concentration that significantly induced HO-1 protein in previous 
experiments (Figure 4-1A). Kinetic studies revealed the CBD-mediated induction of 
HO-1 mRNA to be time-dependent. The enhancement of HO-1 mRNA expression 
was significant after 6 h (2.7-fold), peaked after 24 h with a 7.3-fold increase and then 
declined to a 4.2-fold increase during the 48-h incubation (Figure 4-2B). Accordingly, 
HO-1 protein expression was progressively increased up to 6.3-fold during a 48-h 
incubation with 6 µM CBD (Figure 4-2C). Again, and in consistence to the data 
obtained previously (Figure 4-1A, page 37; Figure 4-2A), there was no induction of 
HO-2 mRNA or protein expression at any incubation time tested (see suppl. 
Figure 12-5, page 115). 
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4.3 Involvement of cannabinoid-receptor signaling in 
CBD-mediated induction of HO-1 
The underlying mechanisms of CBD’s action as well as its molecular targets in cells 
are still not fully identified and may vary dependent on cell type and conditions. 
Therefore, a potential participation of important and well-known cannabinoid-
activated receptors in CBD-mediated induction of HO-1 was investigated 
(Figure 4-3).  
To this end, HUASMC, treated with 10 µM CBD or the corresponding vehicle, were 
first analyzed for the presence of CB1R, CB2R, GPR55, and TRPV1 (Figure 4-3A, A1). 
All of the above-mentioned target receptors were expressed by HUASMC 
(Figure 4-3A, A1). Additionally, the protein expressions of these receptors were 
neither increased nor decreased after a 24-h incubation with CBD as shown by 
Western blot analysis (Figure 4-3A, A1). 
Figure 4-2: Effect of CBD on HO-1 and HO-2 mRNA and protein expression in HUASMC. 
Cells were incubated for 24 h with increasing concentrations (0.1–10 µM) of CBD (A) or with 6 µM 
CBD for the indicated times (B, C). After incubation, cells were analyzed for mRNA expression of 
HO-1 (A, B) and HO-2 (B) or protein expression of HO-1 (C). Expression values were normalized to 
β-actin. Percent control represents comparison with the corresponding vehicle-treated, time-matched 
group (set as 100%). Values are means ± SEM of n = 6 (A), n = 3–5 (B) or n = 3 (C) experiments. 
*P < 0.05 vs. time-matched vehicle control; one-way ANOVA plus Dunnett post hoc test (A) or 
Student’s two-tailed t test (B, C). 
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Figure 4-3: Presence of potential target receptors of CBD in HUASMC and investigation of 
their involvement in CBD-mediated induction of HO-1 protein. Analysis of target receptor 
presence was performed by Western blot following a 24-h incubation with 10 µM CBD or the 
corresponding vehicle (A, A1). For investigation of receptor involvement, HUASMC were 
pre-incubated with AM251 (CB1R antagonist), AM630 (CB2R antagonist), capsazepine (TRPV1 
antagonist) O-1602 (GPR55 agonist) or O-1918 (GPR55 antagonist) for 1 h and then further 
co-incubated with (B, D) or without (C, E) 10 µM CBD for 24 h. Following incubation, cells were 
harvested and lysates were analyzed for protein expression of target receptors (A, A1) or HO-1 (B–E) 
via Western blot. Samples and control were adjusted to equal amounts of the respective vehicles. 
Protein expression values were normalized to β-actin. Percent control represents the comparison with 
the corresponding vehicle-treated, time-matched group (set as 100%). Values are means ± SEM of 
n = 3 (A), n = 5 (B, C, D) or n = 6 (E) experiments. *P < 0.05 vs. time-matched vehicle control; 
one-way ANOVA plus Šidák post hoc test. Statistical analysis was performed using Student’s two 
tailed t test (A), one-way ANOVA plus Šidák post hoc test (B, D) or one-way ANOVA plus Dunnett 
post hoc test (C, E) and revealed no other significant differences between the analyzed groups. 
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Further experiments aimed to investigate the involvement of these 
cannabinoid-activated receptors in the CBD-mediated induction of HO-1 protein in 
HUASMC (Figure 4-3B, D). In order to block the receptor signaling, HUASMC were 
pre-incubated for 1 h with antagonists targeting CB1R (AM251), CB2R (AM630), 
TRPV1 (capsazepine) and GPR55 (O-1918) followed by a 24-h co-incubation with 
CBD (10 µM, Figure 4-3B, D). Additionally, a potential antagonistic effect of CBD on 
GPR55 was investigated using the GPR55 agonist O-1602 (Figure 4-3D). Blocking of 
receptor signaling by pre-incubation with antagonists targeting CB1R, CB2R, TRPV1 
and GPR55 did not alter the CBD-mediated induction of HO-1 protein in HUASMC 
after a 24-h co-incubation with 10 µM CBD (Figure 4-3B, D). Similarly, 
pre-incubation with the GPR55 agonist O-1602 prior to treatment with 10 µM CBD 
did not alter the CBD-mediated induction of HO-1 protein expression (Figure 4-3D). 
Finally, a 24-h incubation with the receptor activity-modulating substances (1 µM) 
alone had no impact on HO-1 protein expression compared to the corresponding 
vehicle-treated groups (Figure 4-3C, D).  
4.4 Involvement of ROS in CBD-mediated induction of HO-1 
The general mechanism leading to the induction of HO-1 is described to involve a 
ROS-dependent electrophilic attack leading to an Nrf2-mediated activation of 
HMOX1 transcription [61, 63–65]. In order to examine an involvement of ROS in the 
CBD-mediated induction of HO-1, the oxidant-scavenging glutathione system was 
strengthened by pre-incubation with the glutathione precursor NAC (for details see 
suppl. Figure 12-2, page 112) prior to a 24-h co-incubation with CBD at 10 µM 
(Figure 4-4A). The Western blot analysis of HO-1 protein revealed that the 
CBD-mediated HO-1 induction, which resulted in a 3.7-fold increase (vs. control), 
was significantly reduced by pre-incubation with NAC at 0.5–3 mM (Figure 4-4A). 
Herein, NAC, at any concentration tested, did not alter HO-1 protein expression 
per sel (Figure 4-4A). Based on these results, the potential pro-oxidant capability of 
CBD was investigated in subsequent flow cytometry-based analyses using the 
ROS-sensitive probe CellROXTM green (Figure 4-4B–E). In an exemplary experiment, 
HUASMC were pre-incubated with NAC or CBD prior to a 1-h co-incubation with 
the ROS inducer TBHP (Figure 4-4C). TBHP strongly increased the mean 
fluorescence intensity (MFI) of CellROXTM green-stained HUASMC (Figure 4-4C, 
red line), whereby the MFI of CellROXTM green in TBHP-treated cells was reduced 
by pre-incubation with NAC (0.5 µM, Figure 4-4C, green line).  
  
                                              
l from the Latin: by or of itself 
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In contrast, pre-incubation with CBD at 6 µM (Figure 4-4C, yellow line) or 10 µM 
(Figure 4-4C, violet line) further enhanced the TBHP-mediated increase in the MFI of 
CellROXTM green-stained HUASMC.  
Additional experiments were performed to further substantiate the relation between 
ROS generation and HO-1 induction mediated by CBD (Figure 4-4B, D–E). For that 
reason, cells were pre-incubated for 1 h with 3 µM NAC prior to a 4-h co-incubation 
with CBD at 6 µM (Figure 4-4B, D) or 10 µM (Figure 4-4B, E) followed by flow 
cytometry analysis. The MFI of CellROXTM green-stained HUASMC was raised by 
15% after a 4-h incubation with 6 µM CBD (Figure 4-4B, D, red line) and was 
significantly increased to 130% at 10 µM CBD (Figure 4-4B, E, red line).  
Figure 4-4: Effect of NAC on CBD-mediated induction of HO-1 protein and ROS generation 
generation in HUASMC. Cells were pre-incubated for 1 h with NAC at indicated concentrations 
prior to co-incubation with 10 µM CBD for 24 h (A). For detection of ROS generation (B–E), cells 
were pre-incubated with 0.5 mM (C) or 3 mM NAC (B, D–E) followed by a 4-h co-incubation with 
CBD as indicated. The ROS-inducing substance TBHP (250 µM) was added as a positive control 1 h 
prior to sample preparation. Following incubation, cells were harvested and analyzed for HO-1 
protein expression (A) or oxidative stress level using flow cytometry (B–E). Protein expression values 
were normalized to β-actin. Percent control represents the comparison with the corresponding 
vehicle-treated, time-matched group (set as 100%). Values are means ± SEM of n = 4 (A), n = 6 (B, 
D–E) or n = 1 (C) experiments. *P < 0.05 vs. time-matched vehicle control; #P < 0.05 vs. 
CBD-treated group; one-way ANOVA plus Šidák post hoc test. 
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Additionally, the CBD-mediated enhancement in the MFI of CellROXTM 
green-stained HUASMC was significantly attenuated by the pre-incubation with 3 mM 
NAC at both 6 µM and 10 µM CBD (Figure 4-4B, D–E, green lines). The flow 
cytometry-based analysis of cell death, which was accomplished in parallel to ROS 
detection by co-staining with SYTOXTM red, however, revealed no significant 
increases of SYTOXTM red-stained cells after treatment with CBD alone or in 
combination with NAC (Figure 4-4B). 
4.5 Investigation of HUASMC phenotype in experimental conditions 
Dependent on diverse circumstances, VSMC possess the ability to switch between a 
contractile/quiescent and a synthetic/proliferative phenotype [3, 257]. To classify the 
phenotype of HUASMC in these experiments, cells were subjected to differently 
composed media for 24 h followed by the analysis of proliferation using the BrdU 
incorporation assay (Table 4-1). The here used media were cSMCGM and rSMCGM 
(FCS content as indicated). Withdrawal of growth factors (rSMCGM, 5% FCS) 
significantly decreased proliferation of HUASMC to 60% compared to incubation in 
cSMCGM (5% FCS; set as 100%). 
Comparison of the rSMCGM-incubated cells showed that the reduction of serum 
content further attenuated the proliferation of HUASMC. In detail, the proliferation 
was decreased by 52% (rSMCGM, 2% FCS) and 96% (rSMCGM, 0% FCS) when 
compared to incubation in rSMCGM containing 5% FCS (set as 100% in this 
comparison). Thus, HUASMC seeded in cSMCGM showed an enhanced proliferation 
dependent on the presence of growth factors and serum content. Another well-known 
stimulant of VSMC activation, resulting in increased proliferation and migration, is 
PDGF. The optimal concentration of PDGF to stimulate HUASMC was determined 
Table 4-1: Effect of media composition on proliferation of HUASMC 
Medium FCS content 
BrdU incorporation 
(% Control) 
cSMCGM FCS (5%) 100.0 ± 1.1 
rSMCGM FCS (5%) 60 ± 3 * 
rSMCGM FCS (2%) 29 ± 3 # 
rSMCGM FCS (0%) 2.4 ± 0.6 # 
 
Note: Cells were incubated in cSMCGM (containing supplements and 5% FCS) or rSMCGM (no 
supplements, FCS content as indicated) for 48 h followed by analysis of BrdU incorporation. Percent 
control represents comparison with the corresponding cSMCGM-incubated, time-matched group (set 
as 100%). Values are means ± SEM of n = 8 experiments. *P < 0.05 vs. cSMCGM; #P < 0.05 vs. 
rSMCGM (5% FCS); one-way ANOVA plus Šidák post hoc test. 
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in preliminary experiments (Table 4-2). Herein, proliferation was concentration-
dependently increased after a 24-h incubation with PDGF resulting in a maximum 
proliferation of 219% vs. vehicle control (100%) at 60 ng/ml PDGF (Table 4-2). 
However, for specific stimulation of VSMC, a PDGF concentration of 20 ng/ml, 
resulting in a proliferation of 196% vs. vehicle control, was considered ideal. 
These results suggest that HUASMC incubated in cSMCGM do also represent a 
synthetic/proliferative phenotype. Therefore, experiments investigating effects of 
CBD on potential disease-associated features of HUASMC were performed in either 
cSMCGM (5% FCS) or using a combination of rSMCGM (2% FCS) and treatment 
with PDGF (20 ng/ml) as a specific stimulator of the synthetic/proliferative 
phenotype. 
4.6 Effect of CBD on proliferation and viability of HUASMC 
Further experiments analyzing cell viability and proliferation were performed to 
investigate the effects of CBD on cellular functions of HUASMC (Figure 4-5). As 
shown in Figure 4-5A, cell viability, as analyzed by trypan blue exclusion staining, was 
not affected after a 48-h incubation with CBD at concentrations of 0.1–10 µM. 
Indeed, there was a slight, yet not significant, concentration-dependent increase in cell 
viability. In contrast, a 48-h incubation with CBD concentration-dependently 
inhibited proliferation of HUASMC (Figure 4-5B). Here, proliferation was 
significantly decreased to 75% and 62% vs. vehicle control (100%) at 6 µM and 10 µM 
CBD, respectively (Figure 4-5B). This anti-proliferative effect was also visible in 
microphotographs showing cell densities of the cultured monolayers (Figure 4-5D). 
Herein, vehicle-treated cells, which were seeded at subconfluence in the beginning of 
Table 4-2: Effect of PDGF on proliferation of HUASMC 
Treatment 
BrdU incorporation 
(% Control) 
Vehicle 100 ± 3 
PDGF (10 ng/ml) 182 ± 12 * 
PDGF (20 ng/ml) 196 ± 10 * 
PDGF (40 ng/ml)  215 ± 14 * 
PDGF (60 ng/ml) 219 ± 14 * 
 
Note: Cells seeded in rSMCGM (no supplements, 2% FCS) were incubated with different 
concentrations of PDGF for 24 h prior to analysis of BrdU incorporation. Percent control represents 
comparison with the respective vehicle-treated group (set as 100%). Values are means ± SEM of 
n = 10–14 experiments. *P < 0.05 vs. vehicle-treated group; one-way ANOVA plus Dunnett post 
hoc test. 
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the experiment, formed a confluent monolayer (Figure 4-5D1). In contrast, the 
monolayer density was reduced after incubation with increasing concentrations of 
CBD (Figure 4-5D2–D4). Kinetic studies revealed that proliferation was significantly 
inhibited by 22% and 17% after incubation with 6 µM CBD for 24 h and 48 h, 
respectively (Figure 4-5C).  
Figure 4-5: Effect of CBD on viability and proliferation of HUASMC. Cells were incubated for 
48 h with indicated concentrations of CBD (A, B) or with 6 µM CBD for the indicated times (C). 
Following incubation, cells were analyzed for viability via trypan blue exclusion staining (A) or 
proliferation using BrdU incorporation assay (B, C). For visualization, unstained monolayers were 
photographed in culture at 10X magnification using a digital microscope camera (D). Percent control 
represents comparison with the corresponding vehicle-treated, time-matched group (set as 100%). 
Values are means ± SEM of n = 4 (A) or n = 10–12 (B, C) experiments. *P < 0.05 vs. time-matched 
vehicle control; one-way ANOVA plus Dunnett post hoc test (A, B) or Student’s two-tailed t test (C). 
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4.7 Involvement of receptor-signaling in CBD-mediated 
anti-proliferative effects 
In order to investigate the underlying mechanism of CBD-mediated anti-proliferative 
effects in HUASMC, cells were pre-incubated for 1 h with substances targeting CB1R 
(AM251), CB2R (AM630), TRPV1 (capsazepine) and GPR55 (O-1918, antagonist; 
O-1602; agonist) followed by a 24-h co-incubation with CBD (10 µM, Figure 4-6A). 
Similar to the results mentioned before (Figure 4-5B, page 45), incubation with 10 µM 
CBD significantly decreased the proliferation of HUASMC resulting in a maximum 
proliferation of 52% vs. vehicle-treated control (100%, Figure 4-6A). Pre-incubation 
with the corresponding receptor activity-modulating substances did not prevent or 
attenuate this effect (Figure 4-6A). Indeed, pre-incubation with the GPR55 agonist 
O-1602 enhanced the anti-proliferative effect of CBD by 2.1-fold, resulting in 24% 
BrdU incorporation vs. vehicle-treated control (100%, Figure 4-6A). Additionally, 
substance-specific effects on cell proliferation were excluded by incubation of 
HUASMC with these substances in the absence of CBD (Figure 4-6B). Herein, none 
of the receptor activity modulating substances per se significantly altered the 
proliferation of HUASMC after a 24-h incubation (Figure 4-6B). 
Figure 4-6: Involvement of receptor-signaling in CBD-mediated anti-proliferative effects in 
HUASMC. For investigation of receptor involvement in anti-proliferative effects of CBD, 
HUASMC were pre-incubated with AM251 (CB1R antagonist), AM630 (CB2R antagonist), 
capsazepine (TRPV1 antagonist), O-1602 (GPR55 agonist) or O-1918 (GPR55 antagonist) for 1 h 
and then further co-incubated with (A) or without (B) 10 µM CBD for 24 h. Following incubation, 
cell proliferation was analyzed via BrdU incorporation assay. Percent control represents comparison 
with the corresponding vehicle-treated, time-matched group (set as 100%). Values are means ± SEM 
of n =10–12 (A) or n = 7–8 experiments. *P < 0.05 vs. time-matched vehicle control; one-way 
ANOVA plus Šidák post hoc test (A) or one-way ANOVA plus Dunnett post hoc test (B). 
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4.8 Involvement of HO-1 in CBD-mediated anti-proliferative effects 
and viability in HUASMC: The SnPPIX approach 
The results mentioned before (chap. 4.7, page 46, Figure 4-6) indicate that the 
anti-proliferative effects of CBD are not mediated by the cannabinoid-activated 
receptors CB1R, CB2R, TRPV1, and GPR55. Therefore, additional experiments aimed 
to address a possible relation between the CBD-mediated anti-proliferative effects and 
the induction of HO-1 in HUASMC (Figure 4-7). The functional role of HO-1 in 
CBD’s anti-proliferative effects was investigated using the two previously defined 
culturing setups to promote a disease-associated behavior of HUASMC (see chap. 4.5, 
page 43). 
In order to block HO-1 activity, cells were pre-incubated with 10 µM of the HO-1 
inhibitor SnPPIX prior to a co-incubation with CBD. The proliferation of HUASMC 
was significantly attenuated after a 48-h incubation with 6 µM and 10 µM CBD, 
resulting in 87% and 68% BrdU incorporation vs. vehicle control (100%, 
Figure 4-7A). However, pre-incubation with SnPPIX did not prevent or attenuate the 
anti-proliferative effects of CBD. Indeed, the inhibition of HO-1 activity by SnPPIX 
alone decreased the proliferation of HUASMC (SnPPIX: 87% vs. vehicle control 
[100%]) and slightly enhanced the CBD-mediated anti-proliferative effects 
(Figure 4-7A). Additionally, the flow cytometry-based analyses of apoptosis revealed 
that the viability of HUASMC was not decreased after a 48-h incubation with CBD 
alone (6 µM and 10 µM, Figure 4-7B, C1–3). The mean amounts of viable cells were 
89.2% (vehicle treated), 89.9% (6 µM CBD) and 90.0% (10 µM CBD, Figure 4-7B, 
C1–3). Conversely, the inhibition of HO-1 activity by SnPPIX significantly reduced the 
cell viability and increased the amount of the late apoptotic/necrotic cell population 
when administered alone or in combination with CBD (Figure 4-7B, C4–6). The mean 
amounts of viable cells after treatment with SnPPIX were 77.4% (vehicle treated), 
79.1% (6 µM CBD) and 82.3% (10 µM CBD, Figure 4-7B, C4–6). The mean amounts 
of late apoptotic/necrotic cells after treatment with SnPPIX were 20.38% (vehicle 
treated), 18.64% (6 µM CBD) and 15.4% (10 µM CBD, Figure 4-7B, C4–6).  
In contrast, the mean amounts of the late apoptotic/necrotic cells in absence of 
SnPPIX were 8.1% (vehicle treated), 7.4% (6 µM CBD) and 7.7% (10 µM CBD, 
Figure 4-7B, C1–3). However, the mean proportion of early apoptotic cells, which are 
positive for Annexin V only, was not increased by any treatment and was below 2.1% 
(Figure 4-7B, C1–6). Additional experiments targeted to investigate the role of HO-1 in 
the impact of CBD on PDGF-mediated proliferation of HUASMC (Figure 4-7D). 
For this purpose, cells were cultured in rSMCGM and pre-incubated with SnPPIX for 
1 h prior to a 24-h co-incubation period in presence of CBD and PDGF or 
corresponding vehicles (Figure 4-7D).  
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Figure 4-7: Effect of HO-1 activity inhibitor SnPPIX on CBD-mediated anti-proliferative 
effects and viability of HUASMC. Cells were pre-incubated for 1 h with 10 µM SnPPIX or the 
corresponding vehicle followed by a 48-h co-incubation period with vehicle or CBD as indicated 
before analysis of proliferation using BrdU incorporation assay (A) or flow cytometry-based analysis 
of apoptosis (B). Exemplary images of flow cytometry analysis are shown in (C). For specific 
stimulation, cells seeded in rSMCGM were pre-incubated for 1 h with 10 µM SnPPIX or the 
corresponding vehicle followed by a 24-h co-incubation period with vehicle or CBD as indicated 
prior to analysis of BrdU incorporation (D). For visualization, unstained monolayers were 
photographed in culture at 10X magnification using a digital microscope camera (E). Percent control 
represents comparison with the corresponding vehicle-treated, time-matched group (set as 100%). 
Values are means ± SEM of n = 10–12 (A, D) or n = 8 (B) experiments. *P < 0.05 vs. time-matched 
(PDGF-free) vehicle control or as indicated; #P < 0.05 vs. PDGF-treated vehicle control one-way 
ANOVA plus Šidák post hoc test. 
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Incubation with PDGF per se significantly enhanced the proliferation of HUASMC up 
to 170% vs. vehicle control (100%, Figure 4-7D). This effect was also visible by 
changes in monolayer density and cell organization compared to vehicle-treated cells 
(Figure 4-7E1–2). Presence of CBD at 6 µM and 10 µM significantly reduced this 
pro-proliferative effect of PDGF, resulting in 118% and 52% BrdU incorporation, 
respectively (Figure 4-7D). This anti-proliferative effect was also recognizable in 
microphotographs, showing a considerably reduced cell density in the presence of 
PDGF by CBD at 6 µM and 10 µM, respectively (Figure 4-7E2–4). Similar to the 
results in Figure 4-7A, presence of SnPPIX per se reduced the PDGF-induced 
proliferation of HUASMC to 133% (Figure 4-7D). According to the previous results, 
co-incubation with SnPPIX neither significantly enhanced nor attenuated the 
anti-proliferative effects of CBD under these conditions (Figure 4-7D). 
 
4.9 Involvement of HO-1 in CBD-mediated anti-proliferative effects 
and viability in HUASMC: The siRNA approach 
In order to exclude possible off-target effects of SnPPIX, additional siRNA 
approaches were performed to knock down HO-1 protein expression (Figure 4-8). 
HO-1 protein was significantly increased to 180% and 280% by CBD at 6 µM and 
10 µM, respectively (Figure 4-8A). Administration of siRNA specifically targeting 
HO-1 significantly attenuated the CBD-mediated induction of HO-1 by 75% and 
50% at 6 µM and 10 µM CBD, respectively (Figure 4-8A). Likewise, the basal protein 
expression of HO-1 was reduced by 78% after transfection with HO-1 siRNA 
(Figure 4-8A).  
Similar to the above-mentioned results using SnPPIX (see chap. 4.8, page 47, 
Figure 4-7A), knockdown of HO-1 further enhanced the CBD-mediated 
anti-proliferative effects after a 24-h incubation albeit being anti-proliferative per se 
(Figure 4-8B). According to the previous results (see chap. 4.8, page 47, Figure 4-7B), 
viability analyses using vital staining showed a significant loss of cell viability in 
HUASMC after knockdown of HO-1 in the presence of CBD at 6 µM and 10 µM, 
respectively (Figure 4-8C). However, administration of HO-1 siRNA per se did not 
affect cell viability (Figure 4-8C). Cell viability of control cells that were transfected 
with a non-targeting siRNA (NON) was not attenuated in presence of CBD 
(Figure 4-8C). Further characterization of the CBD-mediated cell death occurring in 
cells depleted of HO-1 was performed by flow cytometry-based analyses of apoptosis 
(Figure 4-8D). The results once more showed that the amount of viable cells was not 
decreased by CBD per se (Figure 4-8D).  
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Figure 4-8: Effect of HO-1 siRNA on CBD-mediated anti-proliferative effects and viability of 
HUASMC. Cells were transfected with HO-1 specific or non-targeting siRNA (NON) prior to 
stimulation with CBD as indicated for 48 h (A, C, D) or 24 h (B). Following incubation, cells were 
analyzed for protein expression of HO-1 (A), BrdU incorporation (B), viability (C) or apoptosis (D). 
Representative images of flow cytometry-based analysis of apoptosis are shown in (E). Protein 
expression values were normalized to β-actin. Percent control represents comparison with the 
corresponding NON-transfected, time-matched group (set as 100%). Values are means ± SEM of 
n = 4 (A), n = 11–12 (B), n = 3 (C) or n = 9 (D) experiments. *P < 0.05 vs. time-matched 
NON-transfected vehicle control; #P < 0.05 vs. concentration-matched NON-transfected sample; 
one-way ANOVA plus Šidák post hoc test. 
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The mean amounts of viable cells after transfection with the non-targeting siRNA 
(NON) were 90.2% (vehicle treated), 91.7% (6 µM CBD) and 90.7% (10 µM CBD, 
Figure 4-8D, E1–3). In contrast, the presence of HO-1 siRNA significantly reduced the 
number of viable cells Figure 4-8D, E4–6). The mean amounts of viable cells after 
transfection with HO-1 siRNA were 87.2% (vehicle treated), 86.5% (6 µM CBD) and 
85.9% (10 µM CBD, Figure 4-8D, E4–6). The apoptotic or late apoptotic/necrotic cell 
populations of HUASMC were not increased after a 48-h treatment with CBD alone 
(Figure 4-8D, E1–3). However, in accordance to the drastic loss of cell viability (see 
vital-staining, Figure 4-8C), both apoptotic and late apoptotic/necrotic cell 
populations were increased in HO-1 siRNA-transfected cells in presence of CBD 
(Figure 4-8D, E4–6). The mean amounts of apoptotic cells after transfection with 
HO-1 siRNA were 4.4% (vehicle treated), 4.9% (6 µM CBD) and 4.4% (10 µM CBD, 
Figure 4-8D, E4–6). The mean amounts of late apoptotic/necrotic cells after 
transfection with HO-1 siRNA were 7.1% (vehicle treated), 7.1% (6 µM CBD) and 
8.7% (10 µM CBD, Figure 4-8D, E4–6). 
4.10  Role of HO-1 in CBD-mediated anti-migratory effects 
VSMC of the synthetic/proliferative phenotype are also capable of enhanced 
migration [3]. Therefore, effects of CBD on HUASMC migration towards PDGF 
(20 ng/ml) as a chemoattractant were analyzed using a modified Boyden chamber 
assay. The role of HO-1 in this process was investigated using both SnPPIX 
(Figure 4-9A, B1) and HO-1-specific siRNA (Figure 4-9C–F). To ensure specific 
migration towards the chemoattractant PDGF in both approaches, HUASMC were 
cultured in rSMCGM for the whole time of the experiment. As shown in Figure 4-9A, 
B1–2, migration of HUASMC was significantly increased in presence of PDGF 
resulting in 330% migration vs. PDGF-free vehicle control (100%). Pre-incubation 
with CBD (10 µM) almost completely inhibited this pro-migratory effect, resulting in 
139% migration (Figure 4-9A, B4). However, when tested at a concentration of 6 µM, 
the anti-migratory effect of CBD did not reach significance (P = 0.366, one-way 
ANOVA plus Šidák post hoc test, n = 15, Figure 4-9A, B3). Similar to the previous 
results (chap. 4.8, page 47, Figure 4-7A, D), inhibition of HO-1 activity by 
pre-incubation with 10 µM SnPPIX did not attenuate or prevent the CBD-mediated 
anti-migratory effect (Figure 4-9A, B2–7). Indeed, inhibition of HO-1 activity enhanced 
the anti-migratory effects of CBD, being slightly anti-migratory per se (Figure 4-9A,  
B2–7). Using HO-1-specific siRNA, both the CBD-mediated and the basal HO-1 
protein expressions were significantly knocked down (Figure 4-9C, D). Herein, the 
CBD-mediated HO-1 protein expression (6 µM CBD: 290% vs. vehicle control) was 
reduced to 30% (Figure 4-9C).  
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Figure 4-9: Role of HO-1 in CBD-mediated anti-migratory effects in HUASMC. Cells, seeded 
in rSMCGM (no supplements, 2% FCS), were pre-incubated for 1 h with the HO-1 activity inhibitor 
SnPPIX (10 µM) prior to a 24-h co-incubation period with vehicle or CBD at indicated 
concentrations. Afterwards, viable cells were transferred into Falcon® cell culture inserts and 
migration towards PDGF (20 ng/ml) or appropriate vehicle was run for 6 h (A, B). Cells were 
transfected with HO-1-specific or non-targeting siRNA (NON) and incubated in rSMCGM for 24 h. 
For Western blot analysis (C, D), viable cells were transferred into 6-wells and incubated with CBD 
or corresponding vehicle for 6 h prior to sample preparation. For migration (E, F), viable cells were 
transferred into Falcon® cell culture inserts and incubated with CBD or corresponding vehicle for 1 h 
prior to initiation of a 6-h migration towards PDGF (20 ng/ml). Inserts were prepared and cells in 
five randomly selected fields per insert were counted. Representative images of migration analyses are 
shown in (B, G). Percent control represents comparison with the corresponding NON-transfected, 
vehicle-treated group (set as 100%). Values are means ± SEM of n = 15 (A), n = 3 (C), n = 6 (D), 
n = 28–36 (E) or n = 25 (F) experiments. *P < 0.05 vs. PDGF-free vehicle control or as indicated; 
#P < 0.05 vs. PDGF-treated vehicle control; $P < 0.05 as indicated; one-way ANOVA plus Šidák 
post hoc test. 
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Similarly, 10 µM CBD enhanced the HO-1 protein expression in HUASMC to 150% 
vs. vehicle control (Figure 4-9D). This effect was significantly attenuated (40% vs. 
vehicle control) by HO-1 siRNA (Figure 4-9D). Similar to the above-mentioned 
results (Figure 4-9A), migration of HUASMC was significantly enhanced in presence 
of PDGF (Figure 4-9E, F, G1-2). Accordingly, CBD at 6 µM (Figure 4-9E, G3) or 
10 µM (Figure 4-9F, G4) significantly inhibited the PDGF-induced migration of 
HUASMC transfected with non-targeting siRNA (NON). However, using this 
approach, knockdown of HO-1 protein expression did not alter the CBD-mediated 
inhibition of PDGF-induced migration (Figure 4-9E–F, G5–7). 
4.11 Role of CBD-mediated ROS in anti-proliferative effects 
and cell death of HUASMC 
Since anti-proliferative and anti-migratory effects of CBD could not be assigned to 
HO-1 by the previous experiments, additional experiments aimed to investigate the 
role of the CBD-mediated ROS-signaling with regard to proliferation and cell death of 
HUASMC (Figure 4-10A–D). In order to examine the effects mediated by 
CBD-mediated ROS production or ROS-signaling, cells were pre-incubated with the 
glutathione precursor NAC (for details see suppl. Figure 12-2, page 112). According 
to the previous results showing the correlation between CBD-treatment, 
ROS-signaling and induction of HO-1 (chap. 4.4, page 41), pre-treatment with NAC 
at a concentration of 0.1 mM significantly attenuated the CBD-mediated induction of 
HO-1, indicating a reduction of ROS-signaling under these conditions (Figure 4-10A). 
Herein, HO-1 protein expression was not altered after incubation with NAC alone 
(Figure 4-10A). Analysis of cell proliferation by BrdU incorporation assay after a 24-h 
incubation confirmed the previously detected anti-proliferative effect of CBD, which 
was significant at concentrations of 6 µM and 10 µM, respectively (Figure 4-10B). 
Herein, proliferation of HUASMC was reduced to 81% and 71% vs. vehicle control 
(100%). However, the CBD-mediated anti-proliferative effect was neither attenuated 
nor enhanced in presence of NAC, indicating that ROS-signaling may not contribute 
to this effect (Figure 4-10B).  
Referring to the previous results investigating the cell death of CBD-treated 
HUASMC in the absence of functional HO-1 (chap. 4.8, page 47; chap. 4.9, page 49), 
further experiments targeted to examine the role of the CBD-mediated increase of 
ROS in cell death of HUASMC (Figure 4-10C, D). Similar to the previous results, 
administration of CBD alone did not decrease the number of viable cells in the 
analyzed population (Figure 4-10C, D1–3). Although pre-treatment with NAC 
inhibited the CBD-mediated induction of HO-1 (Figure 4-10A), viability and both 
apoptotic and late apoptotic/necrotic cell populations of HUASMC were virtually 
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unaffected in presence of CBD (Figure 4-10C, D4–6). Consequently, these results 
suggest that the CBD-mediated ROS production contributes to induction of the 
anti-oxidant enzyme HO-1 and thus protection of cells against ROS-dependent 
apoptosis. 
 
Figure 4-10: Impact of N-acetylcysteine (NAC) on CBD-mediated anti-proliferative effects 
and viability of HUASMC. Cells were pre-incubated with 0.1 mM NAC or vehicle for 1 h prior to a 
24-h co-incubation with CBD or the corresponding vehicle. This was followed by analysis of HO-1 
protein via Western blot (A), analysis of proliferation using BrdU incorporation assay (B) or flow 
cytometry-based analysis of apoptosis (C) with the representative images shown in (D). Protein 
expression values were normalized to β-actin. Percent control represents comparison with the 
corresponding vehicle-treated, time-matched group (set as 100%). Values are means ± SEM of n = 6 
(A), n = 11–12 (B) or n = 4 (C) experiments. *P < 0.05 vs. vehicle control; #P < 0.05 vs. CBD-treated 
sample; one-way ANOVA plus Šidák post hoc test. 
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5 Discussion 
This project investigated the effect of the phytocannabinoid CBD on the proliferation 
and migration of VSMC, which are both disease-associated features of these cells. 
Aberrant proliferation and migration of VSCM, triggered in particular by 
inflammatory mediators and growth factors, are closely related to the main causes of 
acute cardiovascular events: atherosclerosis and restenosis [31, 258–260].  
By participating in blood vessel formation, VSMC contribute in providing access to 
nutrients and routes of distribution for solid tumors [261, 262]. Thus, recruited and 
activated VSMC are involved in tumour development and cancer progression. 
Strengthening the cellular anti-inflammatory capacity and/or inhibiting the excessive 
proliferation and migration of VSMC may therefore provide benefits in the treatment 
of progressive vascular diseases and cancer. This thesis especially focused the role of 
the anti-oxidant enzyme HO-1 in the CBD-mediated effects in VSMC. The results of 
this work are schematically summarized in Figure 5-1 and discussed below. 
The present study demonstrates that CBD mediates the induction of HO-1 via a 
ROS-dependent mechanism. Additionally, CBD attenuates the disease-associated 
behaviour of VSMC by inhibiting growth factor-initiated proliferation and migration. 
Since both events occurred independently, this study suggests a HO-1-independent 
mechanism that confers the anti-proliferative and anti-migratory effects of CBD. 
Figure 5-1: Schematic representation of the experimental outcomes of this thesis. CBD enters 
the cell and induces the production of ROS in HUASMC. As a protective mechanism, the expression 
of HO-1 is stimulated in a counter-regulatory manner. The glutathione precursor NAC prevents the 
CBD-mediated ROS generation and induction of HO-1. Inhibition of HO-1 by SnPPIX or HO-1 
knockdown by siRNA causes cell death of HUASMC. CBD promotes anti-proliferative and anti-
migratory effects in HUASMC independent of cannabinoid-activated receptors (CB1R, CB2R, TRPV1 
and GPR55), ROS and HO-1. AM251: CB1R antagonist; AM630: CB2R antagonist; bFGF: basic 
fibroblast growth factor; Cpz: capsazepine, TRPV1 antagonist; EGF: epidermal growth factor; HO-1: 
heme oxygenase-1; GPR55: G protein-coupled receptor 55; NAC: N-acetylcysteine; O-1602: GPR55 
agonist; O-1918: GPR55 antagonist; PDGF: platelet-derived growth factor; ROS: reactive oxygen 
species; SnPPIX: tin protoporphyrin IX, inhibitor of HO activity; TRPV1: transient receptor 
potential vanilloid 1  
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Initial experiments examined the potential of synthetic and plant-derived 
cannabinoids to modulate the proteins of the HO system in HUASMC. The results 
demonstrated that the two phytocannabinoids tested, CBD and THC, induced the 
expression of HO-1 but not HO-2. In contrast, the two synthetic cannabinoids tested, 
R(+)-methanandamide and JWH-133, were virtually inactive in this respect. Although 
few studies have been investigating a relation between synthetic cannabinoids and 
HO-1, some have shown that JWH-133, via the induction of HO-1, has positive 
effects in animal models of alcohol- and inflammation-induced liver disease  
[263, 264]. Interestingly, another study reported HO-1 induction in human breast 
cancer cell lines that was induced by JWH-133 but not R(+)-methanandamide [265]. 
Indeed, these reports are, at least in parts, in contrast to the data shown in the present 
study. However, this is the first study providing evidence of a phytocannabinoid-
mediated HO-1 induction in human VSMC. 
The present study concentrated on CBD, which unlike THC lacks psychoactivity. At 
the same time, CBD exerts numerous positive pharmacological effects as assessed in 
animal studies and clinical trials (recently reviewed in [205]). In subsequent analyses, 
the impact of CBD on HO-1 was further characterised. The experimental results 
revealed a CBD-mediated concentration- and time-dependent up-regulation of both, 
HO-1 mRNA and protein level. These results correspond to several studies showing a 
comparable modulation of HO-1 in VSMC by other plant-derived substances  
[14, 15, 17, 21, 68, 97, 99].  
Another set of experiments aimed to investigate the involvement of typical 
cannabinoid-activated receptors, CB1R and CB2R, GPR55 or TRPV1 in the 
CBD-mediated HO-1 induction. The experimental approaches with antagonists 
targeting CB1R, CB2R, TRPV1 and GPR55 and a GPR55 agonist showed no changes 
in the CBD-mediated induction of HO-1. Thus, the participation of these established 
cannabinoid-activated receptors in the HO-1-inducing effect of CBD was excluded.  
Likewise, an induction of HO-1 was observed after chemical inhibition or knockdown 
of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) or 
exogenous addition of AEA in MCF-7 and MDA-MB-231 human breast cancer cell 
lines [265]. Similar to the present study, the induction of HO-1 was independent of 
the cannabinoid-activated receptors CB1R, CB2R and TRPV1 and involved the 
activation of Nrf2 [265]. In accordance with these observations, others have described 
several CB1R/CB2R-independent actions of CBD. For example, CBD at 
concentrations of 1-3 µM led to a reduction of the infarct volume by activating the 
5-HT1A receptor [266]. Thus, CBD contributed to neuroprotection of mice after 
occlusion of cerebral arteries [266]. Similarly, CBD (2.5–5 mg/kg) prevented 
chemotherapy-induced neuropathic pain in female C57BL/6 mice by 5-HT1A 
signaling [267]. This effect was observed when CBD was administered either before 
or after the injection of standard doses of paclitaxel, suggesting both the therapeutic 
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and protective potential of CBD in this context [267]. In this study, CBD  
(0.6–2.7 µM) also exerted positive additive effects by significantly improving the 
paclitaxel-mediated reduction of viability in mouse and human breast cancer cells 
[267]. Thus, CBD contributed to strengthening the effectiveness of chemotherapy 
[267]. Finally, CBD at concentrations of 3–9 µM impaired migration of U87 human 
glioma cells in a Boyden chamber assay [268]. It was shown that this anti-migratory 
effect of CBD occurred independent of CB1R, CB2R and TRPV1, and in a 
PTX-insensitive manner, thereby excluding an involvement of classical cannabinoid 
receptors and/or other Gi/0 protein-coupled receptors [268]. Interestingly, 
controversial data were observed in a study reporting CBD-mediated anti-proliferative 
effects, accompanied by an α-tocopherol-reversible induction of apoptosis, in U86 
and U373 human glioma [269]. Herein, the anti-proliferative effect on cancer cells, 
that was also present in an in vivo xenograft model of human glioma using athymic 
CD-1 nude mice, was partially prevented by the CB2R antagonist SR144528 [269]. 
However, as this anti-proliferative effect of CBD was also insensitive against PTX, a 
Gi/0 protein-coupled receptor-dependent mechanism was finally excluded [269].  
In contrast, and despite its low affinity to CB1R and CB2R [165, 270], some studies 
also reported cannabinoid receptor-dependent effects of CBD. For example, CBD 
reduced the in vitro chemotaxis of peritoneal murine macrophages via CB2R signaling 
[271]. In addition, CBD-mediated activation of both CB1R and TRPV1 led to 
endothelium-dependent vasorelaxation in pre-constricted human mesenteric arteries 
[272]. In contrast, an in vitro GTPγS binding assay revealed that CBD antagonized the 
CP55,940- and WIN55,212-mediated agonistic actions at CB1R and CB2R and 
additionally displayed inverse agonism at CB2R [273]. Likewise, CBD behaved as a 
non-competitive negative allosteric modulator of the THC- and 2-AG-induced actions 
at CB1R in human embryonic kidney cell line HEK293A and in STHdhQ7/Q7 striatal 
neurons [274]. Although excluded in the present study, CBD was shown to exert 
some effects via TRPV1. For example, CBD at a dose of 10 mg/kg mediated an 
anti-hyperalgesic effect in a rat model of acute inflammation via activation of TPRV1 
that was independent of both CB1R and CB2R [182]. Agonism of CBD at TRPV1 also 
increased endocannabinoid levels by inhibition of AEA uptake and hydrolysis [195]. 
Concerning GPR55, CBD antagonised the agonist effect of CP55,940 at this receptor 
in an in vitro GTPγS binding assay [184]. Additionally, an antagonistic action of CBD 
at GPR55 induced mesenchymal stem cell migration by activating ERK MAPK [228]. 
In the present study, the use of GPR55 agonist O-1602 and GPR55 antagonist 
O-1918 excluded GPR55’s involvement in the CBD-mediated induction of HO-1, as 
this effect was neither reversed nor amplified. 
Considering the evolutionarily conserved mechanism of HO-1 induction [63], an 
involvement of ROS in the CBD-mediated induction of HO-1 was examined in 
subsequent experiments. Strengthening the anti-oxidative capability of VSMC by the 
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glutathione precursor NAC countered the CBD-induced HO-1 expression.  
This indicated an involvement of ROS signaling in this process. Accordingly, 
subsequent flow cytometry-based analyses showed that CBD increased the ROS 
generation in HUASMC in a NAC-reversible manner. With regard to oxidative stress, 
the role of CBD has been described as ambivalent as its different effects on the 
cannabinoid-activated receptors. For example, the metabolism of CBD by hepatic 
mouse microsomes led to the suppression of lipid peroxidation in the presence and 
absence of a NADPH-generating system [275]. This indicated potential anti-oxidant 
properties of the phytocannabinoid [275]. In contrast, inhibition of some radical 
scavenging enzymes, such as superoxide dismutase (SOD) and catalase, and CBD 
metabolism-dependent generation of ROS have been found in the same study [275]. 
Additionally, CB1R/CB2R-independent ER stress-induced apoptosis in activated but 
not in control hepatic stellate cells or primary hepatocytes was observed after 
treatment with CBD [276]. These results demonstrated potential beneficial effects of 
CBD on the resolution of liver fibrosis [276]. However, contrasting effects of CBD 
were reported for oligodendrocyte progenitor cells [232]. Herein, CBD at a 
concentration of 1 µM reduced apoptosis following both inflammation-induced ER 
stress and hydrogen peroxide-(H2O2-)induced ROS generation [232]. Likewise, 
intraperitoneal pre-administration of CBD at doses of 2.5–10 mg/kg countered the 
cisplatin-mediated oxidative/nitrative stress-induced inflammation and nephropathy 
in male C57BL/6J mice [277]. Similarly, an intravital microscopy-study showed that 
CBD-mediated the attenuation of lipopolysaccharidem-(LPS-)induced vascular 
changes and inflammation in mouse brain [229]. These findings thus suggest 
beneficial neuroprotective effects in severe complications of bacterially induced 
endotoxic shock [229]. In addition, positive anti-inflammatory effects of CBD were 
also observed in a rat model of I/R injury [243], a mouse model of type I diabetic 
cardiomyopathy [278], and in primary human cardiomyocytes exposed to high glucose 
[278], with CBD reducing inflammation and oxidative/nitrative stress in each of these 
studies. 
This project next aimed to examine the impact of CBD on proliferation and migration 
of HUASMC. Therefore, the proliferative capacity of VSMC was investigated in 
preliminary experiments using different culture conditions. In these experiments, the 
proliferation of HUASMC cultured in cSMCGM was increased compared to cells that 
were cultured under growth factor- and serum-deprivation. Accordingly, Proudfoot 
et al. (2012) described the de-differentiation along with the enhanced proliferation of 
isolated human VSMC, stating that isolated and cultured VSMC represent a 
disease-associated synthetic/proliferative rather than a contractile/quiescent 
phenotype [279]. It was additionally verified by several studies, that the VSMC 
                                              
m Endotoxin component of the outer membrane of Gram-negative bacteria. 
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phenotype can be modulated by mitogensn including growth factors such as bFGF 
and EGF (reviewed in [⁠[3, 257, 280–282]). These both were present in the here used 
cSMCGM. In accordance to several other studies, HUASMC cultured under growth 
factor- and serum-deprivation (rSMCGM conditions) specifically responded to 
stimulation with PDGF by increasing both proliferation and migration  
[16–19, 21, 23, 24]. In the present study, cultivation in cSMCGM or the combination 
of rSMCGM and PDGF-stimulation conferred an amplification of the proliferative 
capacity in HUASMC. These conditions were therefore considered suitable models to 
investigate the effects of CBD against the disease-associated aberrant proliferation 
and migration of VSMC. 
In subsequent functional analyses, this study revealed a CBD-mediated 
concentration-dependent inhibition of growth factor-initiated proliferation and 
migration of HUASMC. Analyses using substances targeting CB1R, CB2R, TRPV1, 
and GPR55 excluded an involvement of these cannabinoid-activated receptors in the 
CBD-mediated anti-proliferative effect. Interestingly, the decrease of HUASMC 
proliferation/migration apparently correlated with the CBD-mediated induction of 
HO-1. Therefore, an involvement of HO-1 was considered a potential mechanism of 
CBD’s anti-proliferative/anti-migratory effects observed in these experiments. 
However, this hypothesis was rejected by experiments targeting both HO-1 activity 
and HO-1 protein expression. In detail, neither HO-1 siRNA nor the inhibitor of 
HO-1 activity, SnPPIX, antagonized the CBD-mediated anti-proliferative/anti-
migratory responses. Since ROS were involved in the CBD-mediated induction of 
HO-1, additional experiments were performed to examine the role of ROS in the 
CBD-mediated modulation of HUASMC proliferation. One study previously reported 
that initiation of ER stress following administration of the potent ER stress inducer 
tunicamycin led to up-regulation of HO-1, inhibition of mitochondrial ROS 
production and modulation of cell cycle-regulatory proteins [19]. Thereby, CBD 
inhibited the PDGF-induced proliferation/migration in rat thoracic aorta SMC 
(RTASMC) without showing significant apoptosis [19]. Although emphasizing the 
anti-oxidant and cytoprotective role of HO-1, it was assumed that the area, where 
positive and negative effects of ER stress are separated, is narrow and requires a fine 
adjustment [19]. In the present study, NAC, at a concentration that sufficiently 
blocked the CBD-mediated ROS-dependent induction of HO-1, failed to attenuate 
the CBD-mediated anti-proliferative effects in HUASMC. Even if not explicitly 
examined here, a ROS-independent effect could also apply to the here reported 
CBD-mediated anti-migratory effects in HUASMC. This study thus demonstrates that 
neither HO-1 nor ROS contributed to CBD’s anti-proliferative effects in HUASMC. 
                                              
n Mitogens are chemical substances that stimulate a cell to initiate cell division (mitosis). 
This is referred to as mitogenesis. 
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Similarly, experiments using wild-type and HO-1-null mouse aortic SMC excluded a 
relation between extracellular acidosis-(EA-)mediated induction of HO-1 and 
inhibition of the PDGF-induced proliferation/migration [283]. An involvement of 
multiple intracellular pathways was thus suggested [283]. Conversely, several other 
studies reported an anti-proliferative/anti-migratory effect of HO-1 in VSMC 
originating from rat thoracic aorta [14, 17, 19, 21, 99, 101, 284], human aorta [15], and 
human saphenous vein [284]. Herein, some plant-derived substances, such as the 
citrus flavonoid naringenin [14], the sesquiterpene lactone eupatolide from 
Inula britannica [21], and the green tea-derived epigallocatechin gallate [15], conferred 
up-regulation of HO-1 and inhibited cytokine- or PDGF-induced proliferation and 
migration in VSMC of different origin. Likewise, atractylenolide Io (AO-I) prevented 
oxidized-low-density lipoprotein-(ox-LDL-)induced production of inflammatory 
cytokines and proliferation in RTASMC via induction of HO-1 [100]. Furthermore, 
AO-1 inhibited foam cell formation and lipid accumulation in peritoneal mice 
macrophages, thereby mediating beneficial anti-atherosclerotic effects [100]. 
Additionally, overexpression of human HO-1 following retroviral transduction of 
RTASMC inhibited cell cycle progression and protected against H2O2-induced 
oxidative injury [95].  
Consistent to the positive findings, chemical inhibition of HO-1 by SnPPIX 
intensified the heme-induced ROS production and the increases of proliferation and 
migration in RTASMC [285]. Accordingly, administration of the HO reaction product 
bilirubin inhibited neointima formation and intimal thickening following carotid artery 
balloon-injury in rats [84]. The underlying mechanism involved the inhibition of both 
cell cycle progression and proliferation of human vascular SMC, thus providing 
beneficial effects against unwanted vascular remodeling after therapeutic intervention 
[84]. Likewise, the exogenous exposure to the gaseous HO reaction product CO 
inhibited the proliferation of HUASMC and human umbilical vein endothelial cells 
(HUVEC) [286].  
The apparently contradictory results for the role of HO-1 may root in 
substance-dependent divergent mechanisms conferring the anti-proliferative and 
anti-migratory effects in SMC. As a matter of fact, anti-proliferative effects in SMC 
were ascribed to both HO-1-dependent and -independent actions. Likewise, it was 
demonstrated that different inducers of HO-1 triggered divergent effects in one cell 
type [287]. In more detail, Loboda et al. (2005) investigated the mechanism of 
VEGF-production in human microvascular endothelial cells using two different 
inducers of HO-1, namely cobalt (II) chloride (CoCl2) and cobalt protoporphyrin IX 
(CoPPIX) [287]. Although both compounds induced HO-1 in these cells, the 
CoCl2-mediated production of VEGF did not involve HO-1 and rather relied on the 
                                              
o One of the major bioactive components of plant rhizomes from Atractylodes macrocephaly. 
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activation of hypoxia-inducible factor 1α (HIF1α) [287]. In contrast, they also showed 
that CoPPIX-mediated VEGF production originated from HO-1 activity and did not 
involve HIF1α [287]. It was further reported that genetic differences in GT-repeat 
length influence the activity of the HO-1 promotor in human VSMC [66]. 
Consequently, species- and donor-dependent genetic differences may affect the 
transcriptional responses and thus the strength of HO-1 activity. These genetic factors 
may be the cause of the divergent outcomes in different studies. 
In terms of the functional investigations in the present study, it is worth mentioning 
that a greater loss in cell viability was observed by use of the chemical inhibitor 
SnPPIX, in contrast to the siRNA-mediated knockdown of HO-1. The loss of 
viability under SnPPIX conditions exclusively increased the late apoptotic/necrotic 
but not the apoptotic cell population. Possibly, this is a consequence of an 
acceleration of apoptosis or toxicity. In contrast, the targeted knockdown of HO-1 by 
siRNA led to a slight reduction in cell viability, but both apoptotic and necrotic 
fractions were increased. This seemed more likely to be the normal course of the 
apoptotic cell death. In the present study, SnPPIX was used at a concentration of 
10 µM. For HO inhibitors, including SnPPIX and zinc protoporphyrin IX (ZnPPIX), 
this concentration is commonly used in in vitro studies investigating the role of HO-1 
in VSMC [17, 18, 21, 21, 68, 97, 99, 246, 285, 288]. The efficiency of SnPPIX to 
inhibit the HO-catalyzed heme degradation reaction has been proven in several 
studies by activity assays [244, 289, 290]. However, studies regarding the selectivity of 
these substances are rare. Nevertheless, non-selective but very potent inhibitory 
effects of SnPPIX on both HO isoenzymes were described [291]. It is therefore 
conceivable that not only the stress response, but also the basic anti-oxidant capacity 
of the cells will decrease. This may explain the resulting differences and the drastic 
loss of cell viability even in the absence of CBD. On the other hand, the targeted 
knockdown of HO-1 significantly reduced the corresponding protein. However, both, 
the residual activity of the remaining HO-1 and a possible compensation by HO-2, 
could mitigate the potential toxic conditions in the presence of CBD. These processes 
may lead to the different outcomes of these experiments. A possible compensatory 
role for HO-2 has been described for human endothelial cells under hypoxic 
conditions [292]. Herein, the expression of HO-1 was decreased under hypoxic 
conditions, whereas the translation of HO-2 transcripts, and thus HO-2 protein 
synthesis, was up-regulated and preserved cell viability under these conditions [292]. 
However, by pointing out that inhibition or knockdown of HO-1 further enhances 
the anti-proliferative and anti-migratory effects of CBD together with the induction of 
apoptotic cell death, the present study substantiates the fundamental cytoprotective 
role of HO-1. Similarly, treatment with the plant-derived triterpenoids maslinic acid 
and oleanolic acid confirmed a protective role of the HO-1 pathway against 
H2O2-induced oxidative stress and apoptosis in RTASMC [68, 97].  
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A protective role of HO-1 has been likewise reported regarding other disease-models 
or cell types. For example, CoPPIX-mediated induction of HO-1 or treatment with 
the CO-releasing molecule-(CORM-)A1 prevented oxidative stress and hepatocyte cell 
death in vitro and in an in vivo model of alcoholic liver disease using female C57BL/6J 
mice [87]. Similarly, CoPPIX-mediated induction of HO-1 protected HUVEC against 
high glucose-mediated oxidative and ER stress and activation of inflammatory and 
apoptotic reactions [90]. It was thereby suggested that HO-1 mediates positive effects 
against diabetes-induced endothelial dysfunction and cardiovascular complications 
[90]. Additionally, endogenous and overexpressed HO-1 prevented 
hypoxia/reoxygenation-(H/R-)induced cell death by inhibiting mitochondrial ROS 
production and stabilization of mitochondrial membrane in H9C2 rat cardiomyocytes 
[293]. Thus, HO-1 provided beneficial effects against myocardial H/R-injury [293]. 
In the present study, subsequent experiments further substantiated the cytoprotective 
role of HO-1 and its compensatory induction following the CBD-mediated ROS 
production. NAC, by mitigating ROS production, prevented both the compensatory 
up-regulation of HO-1 and the cell death mediated by CBD in absence of HO-1. 
According to the results of the study presented here, Scott et al. (2015) observed 
CBD-specific changes in expression and up-regulation of several heat shock proteins 
(HSPs) including HO-1 by ROS generation in T98G and U87MG human 
glioblastoma cell lines [294]. Despite structural similarities between CBD and THC, 
these effects were not observed using THC [294]. In detail, co-incubation with 
non-cytotoxic concentrations of inhibitors targeting some of these HSPs reduced the 
mean inhibitory concentration (IC50) of CBD and markedly induced apoptosis [294]. 
The latter effect was evoked by an increase in the cells’ sensitivity to radiation, which 
may provide an interesting approach for future irradiative glioblastoma therapies 
[294]. Finally, the CBD-mediated increase of HSPs was sensitive against the ROS 
scavenger NAC [294]. This result is in line with the NAC-sensitive CBD-mediated 
induction of HO-1 observed in the present study. The apoptosis-inducing mechanism 
of some cannabinoid receptor agonists, such as THC, AEA and the synthetic THC 
analog HU-210, was investigated in H460 human lung cancer cells [295]. The study 
revealed an increased mitochondrial H2O2 production that was caused by the 
inhibition of the respiratory chain’s mitochondrial complex I [295]. In the case of 
CBD, however, an opposite effect was observed in a model of chemotherapy-induced 
cardiomyopathy in male C57BL/6J mice [296]. Herein, pre-treatment with 
intraperitoneally administered CBD at a dose of 10 mg/kg preserved doxorubicin-
induced cardiotoxicity by several protective mechanisms [296]. These included, for 
example, the reduction of oxidative/nitrative stress, the improvement of 
mitochondrial biogenesis and an increased activity of the respiratory chain’s 
mitochondrial complexes I and II [296]. Similar, a recent study reported that CBD at a 
concentration of 5 µM prevented cytotoxicity and cell death in an oxygen-glucose-
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deprivation/reperfusion- (OGD/R-)model using HT22 mouse hippocampal neuronal 
cells [297]. Herein, the in-depth analyses showed that CBD protected cells from 
OGD/R-induced loss of mitochondrial bioenergetics by stimulating the 
pentose-phosphate pathway of glucose metabolism and reducing oxidative stress 
[297]. Thus, CBD exerted a strong and potential neuroprotective effect against I/R 
injury [297], which is in line with some other studies [221, 223]. Interestingly, in 
animal studies of cerebral ischemia CBD, given at doses of 1 mg/kg or 5 mg/kg, also 
exerted neuroprotective effects even when given after the ischemic insult [220, 222].  
It was therefore assumed that CBD might also mediate beneficial therapeutic effects 
when used as an anti-ischemic drug [220, 222]. 
Regarding the cytoprotective role of HO-1, the suppression of HMOX1 gene 
translation after transfection with the hypoxia-inducible miR-24 showed 
anti-proliferative and anti-migratory effects in human aortic SMC [298]. However, this 
was accompanied by the induction of apoptosis [298]. In addition, Wu et al. (2008) 
reported CBD-dependent cytotoxicity in primary lymphocytes of mice due to 
oxidative stress and induction of apoptosis-indicating caspase-8 [299]. Similar to the 
present study, the CBD-mediated oxidative stress and apoptosis were prevented by 
the pre-treatment with NAC at concentrations up to 1 mM [299]. The same group 
later described a CBD-induced contrasting pro-apoptotic effect between freshly 
isolated and pre-cultured human monocytes [300]. The investigations of this study 
showed a significant decrease in the glutathione content in the freshly isolated 
monocytes [300]. In contrast, the pre-cultured monocytes were insensitive to the 
CBD-induced cytotoxicity due to higher glutathione and HO-1 values [300].  
In the present study, however, VSMC treated with CBD alone did not undergo 
apoptosis as analyzed by flow cytometry and vital staining, even though CBD 
intensely induced the ROS production. 
CBD appears to perform various actions that may depend on the species and cell 
types analyzed and are particularly evident when comparing cancer and non-neoplastic 
cells. Nevertheless, the role of HO-1 in cancer and non-neoplastic cells is also 
regarded as ambivalent. Since HO-1 has positive cell-protective properties, it can also 
protect degenerated cells, thus promoting undesirable effects such as chemoresistance, 
tumor growth and cancer angiogenesis (reviewed in [301, 302]). Recently, potent 
anti-tumor effects of paenolp in MDA-MB-231 human breast cancer cells were 
correlated with a down-regulation of HO-1 [303]. On the other hand, the 
up-regulation of HO-1 by piperlongumineq selectively induced ROS generation and 
apoptosis in MCF-7 human breast cancer but not in MCF10-A human breast 
epithelial cells [304].  
                                              
p A phenolic compound in root barks of Paeonia moutan. 
q A natural alkaloid derived from long pepper. 
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Additionally, in a recent study, the flavonoid fisetinr induced HO-1 up-regulation in 
4T1 and JC mouse breast cancer cells and inhibited matrix metalloproteinases, 
enzymes that are commonly up-regulated in cell migration processes [305]. These 
results therefore indicate also beneficial anti-metastatic effects of HO-1 with respect 
to breast cancer therapy [305]. 
Noteworthy, the up-regulation of HO-1 and the anti-proliferative/anti-migratory 
effects of CBD were significantly detectable at concentrations of 6 µM and 10 µM. 
Although representative of the usual CBD concentrations that range from  
0.1–100 µM in in vitro experiments [232, 242, 269, 272, 275, 294, 299, 300], these 
concentrations are indeed above the therapeutic plasma concentrations of the drug. 
Accordingly, six weeks of oral treatment of Huntington’s disease patients with CBD 
at a dose of 10 mg/kg/day (approx. 700 mg/d) resulted in maximum mean CBD 
plasma peak values of 0.036 µM (equivalent to 11.2 ng/ml) as investigated by 
gas chromatography-mass spectrometry (GC-MS) analysis [306]. Interestingly, another 
recent study reported approximately 20-fold higher maximum CBD plasma 
concentrations of 0.7 µM (equivalent to 221 ng/ml) [307]. This was measured 3 hours 
after simultaneous administration of a single oral dose of CBD (800 mg; equivalent to 
10–15 mg/kg) and a single intravenous dose of fentanyls (0.5 µg/kg) [307]. Given the 
conditions and limitations of cell culture experiments, a direct correlation of in vitro to 
in vivo is rather critical anyway. For example, diverging outcomes between in vivo and 
in vitro studies investigating the CBD-induced production of interleukin (IL) in murine 
macrophages have been shown [271]. Herein, antagonists targeting CB1R and CB2R 
prevented the CBD-mediated increase of IL-12 and the CBD-mediated decrease of 
IL-10 in in vitro experiments, but not in in vivo models [271].  
In summary, the various complex effects of CBD appear to depend on cell type, 
species and experimental conditions. These dependencies complicate both the 
understanding and the targeted investigation of the underlying mechanisms of the 
CBD-mediated anti-proliferative and anti-migratory effects in HUASMC. Although 
cannabinoids have been the focus of research in recent decades, there are likely some 
unexplored targets and mechanisms underlying the cannabinoid-mediated actions. 
However, this study provides the first evidence of a phytocannabinoid-induced 
increase of HO-1 in VSMC by both, CBD and THC. Accompanying the increase in 
HO-1, CBD exerted positive anti-proliferative and anti-migratory effects without 
showing cytotoxicity per se. However, aside from the protection against oxidative 
stress-induced cell death, HO-1 did not contribute to the positive effects mediated by 
CBD in HUASMC. Further studies on the potential vasculoprotective and 
anti-angiogenic properties of CBD are therefore justified. 
                                              
r A flavonoid found in a variety of plants. 
s Opioid. Used for pain-medication and anesthesia.  
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6 Summary 
Cardiovascular diseases and cancer are the most frequent causes of death worldwide. 
Vascular smooth muscle cells (VSMC) are involved in their underlying mechanisms. 
VSMC, physiologically contributing to the maintenance of the vascular tone and the 
regulation of blood pressure, are assigned to a contractile/quiescent phenotype. 
Inflammatory processes and/or released growth factors lead to phenotypic changes in 
VSMC and thus support, for example, wound healing processes. This activated 
phenotype is characterized by a high proliferation and migration rate. It is referred to 
as a synthetic/proliferative or disease-associated phenotype. Uncontrolled activation 
and promotion of this phenotype occurs, for example, in chronic inflammatory 
vascular diseases such as arteriosclerosis. Growth factors, released during tumor 
progression, also support this process and thus enable the development of a tumor 
blood supply. The inhibition of abnormal proliferation and migration of VSMC 
represents a strategy to slow down or even prevent the progression of these diseases. 
Several studies attributed such an anti-proliferative/anti-migratory effect in VSMC to 
heme oxygenase-1 (HO-1). This enzyme is primarily induced under conditions of 
oxidative cell stress and contributes significantly to cell protection through its 
potentially anti-oxidative products. 
Medical research increasingly proves the benefit of cannabinoids, which, among other 
things, have spasmolytic, analgesic, and anti-inflammatory properties. However, 
psychoactive effects limit the therapeutic benefits of several cannabinoids. In contrast, 
the phytocannabinoid cannabidiol (CBD) does not exhibit psychoactivity. It therefore 
represents a particularly interesting candidate for medical purposes. Recently, the 
American approval authority, FDA, licensed a pure CBD preparation for the 
treatment of severe, therapy-resistant forms of epilepsy. 
In the context of this work, the effects of cannabinoids regarding an induction of 
HO-1 in VSMC were examined for the first time. In addition, the effects of CBD on 
proliferation and migration of VSMC and the role of HO-1 in these effects were 
evaluated. Initial experiments demonstrated a strong concentration- and 
time-dependent induction of HO-1 in VSMC by the two phytocannabinoids THC 
and CBD, but not by the synthetic cannabinoids R-(+)-methanandamide and 
JWH-133. This induction could also be demonstrated for CBD at the mRNA level. A 
participation of the cannabinoid-activated receptors CB1R, CB2R, TRPV1 and GPR55 
in the HO-1 induction was experimentally excluded. The use of the glutathione 
precursor N-acetylcysteine (NAC) indicated a participation of reactive oxygen species 
(ROS) in the CBD-mediated induction of HO-1. A CBD-mediated formation of ROS 
was confirmed in flow cytometry-based investigations also using NAC. Based on 
proliferation analyses, experimental conditions promoting the synthetic/proliferative 
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phenotype of VSMC were determined. Subsequent functional analyses showed a 
significant inhibition of proliferation/migration of VSMC by treatment with CBD 
while maintaining cell viability. The role of HO-1 in these effects was investigated by 
both chemical inhibition of activity and by targeted knockdown of HO-1 via RNA 
interference. The inhibition of the activity/expression of HO-1 led to a severe 
reduction of cell viability after treatment with CBD in both experimental approaches. 
Accordingly, the anti-proliferative/anti-migratory effects of CBD were not eliminated, 
but partially enhanced. A participation of ROS in the CBD-mediated anti-proliferative 
effects was excluded by the use of NAC. The use of NAC inhibited both the 
CBD-mediated ROS formation and the HO-1 induction. Nevertheless, cell viability 
was maintained under treatment of CBD. From this, the role of HO-1 as a 
cytoprotective enzyme was demonstrated. A participation of HO-1 in the 
CBD-mediated anti-proliferative/anti-migratory effects was contradicted by the 
investigations. 
Summarizing, this study shows that CBD mediates beneficial effects with regard to 
the excessive proliferation and migration, i. e. disease-associated behavior of VSMC. 
The compensatory induction of HO-1 contributes to the protection of the cells 
against the formation of ROS mediated by CBD. Due to the lack of psychoactivity, 
CBD is still a promising candidate for the treatment of various diseases. The 
mechanism by which CBD mediates its shown anti-proliferative and anti-migratory 
effects needs to be further investigated. 
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7 Zusammenfassung 
Kardiovaskuläre Erkrankungen und Krebs gehören zu den häufigsten Todesursachen 
weltweit. An den zugrundeliegenden Mechanismen sind vaskuläre glatte Muskelzellen 
(VSMC, engl.: vascular smooth muscle cells) beteiligt. VSMC tragen 
physiologischerweise zum Erhalt des Gefäßtonus und zur Regulation des Blutdrucks 
bei und werden einem kontraktilen/ruhendem Phänotyp zugeordnet. Entzündliche 
Prozesse oder freigesetzte Wachstumsfaktoren führen zur phänotypischen 
Veränderung der VSMC und fördern so beispielsweise die Wundheilung. Dieser 
aktivierte Phänotyp zeichnet sich u. a. durch eine hohe Proliferations- und 
Migrationsrate aus. Er wird als synthetischer/proliferierender bzw. als 
krankheitsassoziierter Phänotyp bezeichnet. Eine unkontrollierte Aktivierung und 
Förderung dieses Phänotyps tritt beispielsweise bei chronisch-entzündlichen 
Gefäßerkrankungen wie der Arteriosklerose auf. Auch im Rahmen der 
Tumorprogression freigesetzte Wachstumsfaktoren unterstützen diesen Prozess und 
ermöglichen so den Aufbau einer Tumor-Blutversorgung. Die Hemmung der 
abnormalen Proliferation und Migration der VSMC stellt eine Strategie dar, das 
Fortschreiten dieser Erkrankungen zu verlangsamen oder gar zu verhindern. 
In diversen Untersuchungen konnte ein derartiger anti-proliferativer/ 
anti-migrativer Effekt in VSMC der Hämoxygenase-1 (HO-1) zugeschrieben werden. 
Dieses Enzym wird vorrangig unter Bedingungen des oxidativen Zellstress induziert 
und trägt durch seine potenziell anti-oxidativen Produkte maßgeblich zum Zellschutz 
bei. 
Medizinische Forschungen belegen wiederholt den Nutzen von Cannabinoiden, die 
u. a. krampflösende, schmerzstillende und anti-entzündliche Eigenschaften aufweisen. 
Der therapeutische Nutzen vieler Cannabinoide wird allerdings durch psychoaktive 
Eigenschaften limitiert, die das Phytocannabinoid Cannabidiol (CBD) jedoch nicht 
aufweist. Es stellt somit einen besonders interessanten Kandidaten für medizinische 
Zwecke dar. Erst kürzlich wurde durch die amerikanische Lebensmittel-
überwachungs- und Arzneimittelbehörde (FDA, engl. Food and Drug Administration) 
ein reines CBD-Präparat zur Behandlung schwerer, therapieresistenter 
Epilepsieformen zugelassen. 
Im Rahmen dieser Arbeit wurden erstmals die Effekte von Cannabinoiden 
hinsichtlich einer Induktion der HO-1 in VSMC untersucht. Zudem sollte die 
Wirkung von CBD auf Proliferation und Migration der VSMC sowie die Rolle der 
HO-1 in diesen Effekten evaluiert werden. Erste Untersuchungen zeigten eine starke 
konzentrations- und zeitabhängige Induktion der HO-1 in VSMC durch die beiden 
Phytocannabinoide THC und CBD, nicht jedoch durch die synthetischen 
Cannabinoide R-(+)-Methanandamid und JWH-133. Diese Induktion konnte für 
68 Zusammenfassung 
 
CBD auch auf mRNA-Ebene nachgewiesen werden. Eine Beteiligung der 
Cannabinoid-aktivierten Rezeptoren CB1R, CB2R, TRPV1 und GPR55 an der 
HO-1-Induktion konnte experimentell ausgeschlossen werden. Die Verwendung des 
Glutathionvorläufers N-Acetylcystein (NAC) wies auf eine Beteiligung reaktiver 
Sauerstoffspezies (ROS) an der CBD-vermittelten Induktion der HO-1 hin. Eine 
CBD-vermittelte Bildung von ROS wurde in durchflusszytometrischen 
Untersuchungen ebenso unter Verwendung von NAC belegt. Anhand von 
Proliferationsanalysen wurden experimentelle Bedingungen ermittelt, welche den 
synthetischen/proliferativen Phänotyp der VSMC fördern. Anschließende 
funktionelle Analysen zeigten eine starke Hemmung von Proliferation und Migration 
der VSMC durch Behandlung mit CBD, bei gleichbleibender Viabilität der Zellen. Die 
Rolle der HO-1 in diesen Effekten wurde sowohl durch chemische Hemmung der 
Aktivität als auch durch ein gezieltes Knockdown der HO-1 via RNA-Interferenz 
untersucht. Eine Hemmung der Aktivität/Expression der HO-1 führte in beiden 
experimentellen Ansätzen zu einer starken Reduktion der Zellviabilität nach 
Behandlung mit CBD. Die anti-proliferativen/anti-migrativen Effekte von CBD 
wurden dementsprechend nicht aufgehoben, sondern teilweise verstärkt. Eine 
Beteiligung von ROS an den CBD-vermittelten anti-proliferativen Effekten wurde 
durch den Einsatz von NAC ausgeschlossen. NAC führte sowohl zur Hemmung der 
CBD-vermittelten ROS-Bildung als auch der HO-1 Induktion. Dennoch blieb die 
Zellviabilität unter Behandlung von CBD erhalten. Hieraus lässt sich die Rolle der 
HO-1 als Zellschutz-Enzym belegen. Eine Beteiligung der HO-1 an den 
CBD-vermittelten anti-proliferativen/anti-migrativen Effekten wurde durch die 
Untersuchungen widerlegt. 
Zusammenfassend konnte in dieser Arbeit gezeigt werden, dass CBD vorteilhafte 
Effekte hinsichtlich der überschießenden Proliferation und Migration, also einem 
krankheitsassoziierten Verhalten von VSMC, vermittelt. Die kompensatorische 
Induktion der HO-1 trägt hierbei zum Schutz der Zellen vor der durch CBD 
vermittelten Bildung von ROS bei. Aufgrund fehlender Psychoaktivität ist CBD 
weiterhin ein vielversprechender Kandidat für die Behandlung verschiedener 
Erkrankungen. Der Mechanismus, über den CBD seine hier gezeigten 
anti-proliferativen und anti-migrativen Effekte vermittelt, muss noch näher untersucht 
werden. 
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µM ................................................................................................................ micromol per liter 
  
5-HT .................................................................................... 5-hydroxytryptamine/serotonin 
  
AEA ............................................................... N-arachidonoyl-ethanolamide / anandamide 
AM251 .............................................................. 1-(2,4-dichlorophenyl)-5-(4-iodophenyl)-4- 
methyl-N-piperidin-1-ylpyrazole-3-carboxamide 
AM630 ..................................... [6-iodo-2-methyl-1-(2-morpholin-4-ylethyl)indol-3-yl]-(4-
methoxyphenyl)methanone / 6-iodopravadoline 
APS .................................................................................................... ammonium persulphate 
AV ............................................................................................................................ Annexin V 
  
BACH1 ....................................................................... BTB Domain And CNC Homolog 1 
BCA ............................................................................................................. bicinchoninic acid 
bFGF ....................................................................................... basic fibroblast growth factor 
BrdU ......................................................................................................... bromodeoxyuridine 
BS .................................................................................................................. blocking solution 
  
CBD ........................................................................................................................ cannabidiol 
CBR .................................................................................................... cannabinoid receptor(s) 
cDNA ................................................................................................... complementary DNA 
chap ................................................................................................................................... chapter 
cm2 ................................................................................................................ square centimetre 
CNS ...................................................................................................... central nervous system 
CO ................................................................................................................. carbon monoxide 
CO2 ....................................................................................................................carbon dioxide 
CoCl2 ............................................................................................................ cobalt(II) chloride 
CoPPIX .......................................................................................... cobalt protoporphyrin IX 
CP55,940 .........................(-)-cis-3-[2-hydroxy-4-(1,1-dimethylheptyl)-phenyl]-trans-4-(3-
hydroxypropyl)cyclohexanol 
cSMCGM .................................................................................................. complete SMCGM 
Ct ....................................................................................................................... threshold cycle 
CYP450 ........................................................................................................ cytochrome P450 
  
DMEM ...................................................................... Dulbecco’s modified Eagle’s medium 
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EGF ................................................................................................... epidermal growth factor 
ER ........................................................................................................ endoplasmic reticulum 
ERK ................................................................................ extracellular signal-regulated kinase 
  
FCS ................................................................................................................... fetal calf serum 
Fe ..........................................................................................................chemical element: iron 
Fe2+ ................................................................................................................. divalent iron ion 
FePPIX ................................................................................ iron protoporphyrin IX / heme 
  
g ........................................................................................................................................... gram 
  
h ...................................................................................................................................... hour(s) 
H2O2 ........................................................................................................... hydrogen peroxide 
HCl ................................................................................................................ hydrochloric acid 
HO ...................................................................................................................heme oxygenase 
hPDGF-BB .................................................................................. human PDGF-BB [dimer] 
HRP ..................................................................................................... horseradish peroxidase 
HUASMC .......................................................human umbilical artery smooth muscle cells 
HUVEC ....................................................................human umbilical vein endothelial cells 
  
i. e. ......................................................................................................... id est [lat.: that means] 
I/R .......................................................................................................... ischemia/reperfusion 
IC50 ......................................................................................... mean inhibitory concentration 
INN ................................................................................. international nonproprietary name 
  
JWH-133 ............................................................... 1-deoxy-3-(1',1'-dimethylbutyl)-Δ8-THC 
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Keap1 .......................................................................... Kelch-like ECH-associated protein 1 
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LDL .................................................................................................... low-density lipoprotein 
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MAPK ........................................................................... mitogen-activated protein kinase(s) 
MFI ............................................................................................. mean fluorescence intensity 
Mg2+ ................................................................................................... divalent magnesium ion 
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mRNA ........................................................................................................ messenger RNA(s) 
mW ................................................................................................................................milliwatt 
  
NAC ................................................................................................................ N-acetylcysteine 
NaCl ................................................................................................................ sodium chloride 
NADPH ................ phosphorylated form of reduced nicotinamide adenine dinucleotide 
NaOH .......................................................................................................... sodium hydroxide 
ng/ml ................................................................................................... nanogram per millilitre 
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NON ....................................................................................................... non-targeting siRNA 
Nrf2 ..................................................................... nuclear factor (erythroid-derived 2)-like 2 
  
O-1602 ......................................................... 5-methyl-4-[(1R,6R)-3-methyl-6-prop-1-en-2- 
ylcyclohex-2-en-1-yl]benzene-1,3-diol 
O-1918 ............................... 1,3-dimethoxy-5-methyl-2-[(1R,6R)-3-methyl-6-prop-1-en-2- 
ylcyclohex-2-en-1-yl]benzene 
  
PCR ................................................................................................ polymerase chain reaction 
PDGF ...................................................................................... platelet-derived growth factor 
PI ................................................................................................................... propidium iodide 
pmol .............................................................................................................................. picomol 
PTX .................................................................................................................... pertussis toxin 
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ROS ..................................................................................................... reactive oxygen species 
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RTASMC .................................................................. rat thoracic aorta smooth muscle cells 
  
SDS-PAGE ........................... sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
SEM .............................................................................................. standard error of the mean 
siRNA .............................................................................................. small interfering RNA(s) 
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SMCGM ....................................................................... smooth muscle cell growth medium 
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TBHP ............................................................................................... tert-butyl hydroperoxide 
TBS-T ................................................................................. TRIS-buffered saline/Tween®20 
TC75-flask ............................................. tissue culture flasks with a growth area of 75 cm2 
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TF .............................................................................................................. transcription factor 
THC ................................................................................ Δ9-tetrahydrocannabinol (Δ9-THC) 
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12 Attachment 
12.1 Materials 
Unless otherwise stated, all materials listed have been purchased from German 
suppliers. 
Table 12-1: Cells, cell culture media and supplements 
Product Supplier 
HUASMC PromoCell, Heidelberg 
DMEM  Lonza, Cologne 
- with 4.5 g/L glucose and L-glutamine  
FCS PAN Biotech, Aidenach 
SMCGM  PromoCell, Heidelberg 
- with FCS (5 % [v/v] PromoCell, Heidelberg 
 EGF (0.5 ng/ml PromoCell, Heidelberg 
 bFGF (2 ng/ml) PromoCell, Heidelberg 
 Insulin (5 ng/ml) PromoCell, Heidelberg 
Table 12-2: Chemicals and reagents 
Product Supplier 
AM251 Biomol, Hamburg 
AM630 Biomol, Hamburg 
APS Carl Roth®, Karlsruhe 
Aqua ad iniectabilia Braun Melsungen AG, Melsungen 
Blotting grade blocker Bio-Rad, Munich 
Bromophenol blue Sigma-Aldrich, Taufkirchen 
Capsazepine Sigma-Aldrich, Taufkirchen 
CBD Biotrend AG, Cologne 
DMSO AppliChem, Darmstadt 
DPBS (without Ca2+ and Mg2+ ) PAN Biotech, Aidenach 
Ethanol Central pharmacy, Rostock 
Glycerine (water-free) AppliChem, Darmstadt 
Glycine AppliChem, Darmstadt 
H2O2 Sigma-Aldrich, Taufkirchen 
HCl Merck, Darmstadt 
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Product Supplier 
hPDGF-BB Thermo Fisher Scientific Inc., 
Waltham (MA, USA) 
Isopropanol J. T. Baker, Griesheim 
JWH133 Tocris Bioscience, 
Wiesbaden-Nordenstadt 
Luminol Sigma-Aldrich, Taufkirchen 
Methanol J. T. Baker, Griesheim 
NAC Sigma-Aldrich, Taufkirchen 
NaCl  AppliChem, Darmstadt 
NaOH AppliChem, Darmstadt 
O-1602 Tocris Bioscience, Bristol (UK) 
O-1918 Tocris Bioscience, Bristol (UK) 
p-Coumaric acid Sigma-Aldrich, Taufkirchen 
R-(+)-Methanandamid Tocris Bioscience, 
Wiesbaden-Nordenstadt 
Rotiphorese® Gel 30 Carl Roth®, Karlsruhe 
SDS ultrapure AppliChem, Darmstadt 
SnPPIX (chloride) Enzo Life Sciences GmbH, Lörrach 
TEMED Carl Roth®, Karlsruhe 
THC Lipomed GmbH, Weil am Rhein 
TRIS (ultrapure) AppliChem, Darmstadt 
TRIS/HCl AppliChem, Darmstadt 
Trypan blue solution (0.4 %) ThermoFisher Scientific Inc., Waltham 
(MA, USA) 
Trypsin-EDTA (10X) ThermoFisher Scientific Inc., Waltham 
(MA, USA) 
Tween® 20 Carl Roth®, Karlsruhe 
β-Mercaptoethanol Ferak®, Berlin 
Table 12-3: Assay kits 
Product Supplier 
BrdU cell proliferation ELISA Abcam, Cambridge (UK) 
CellROXTM green flow cytometry 
assay kit 
Thermo Fisher Scientific Inc., 
Waltham (MA, USA) 
Diff Quick staining Labor + Technik Eberhard Lehmann 
GmbH, Berlin 
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Product Supplier 
FITC-Annexin V apoptosis 
detection kit I 
BD Biosciences, Heidelberg 
PierceTM BCA protein assay kit Pierce, Rockford (IL, USA) 
RNeasy Mini kit  Qiagen, Hilden 
TaqMan® RNA-to-CTTM 1-Step kit Thermo Fisher Scientific Inc. 
Table 12-4: Antibodies for Western blot analysis 
Primary antibody Supplier 
CB1R antibody (#sc-293419) Santa Cruz Biotechnology, Inc., 
Heidelberg 
CB2R antibody (#sc-293188) Santa Cruz Biotechnology, Inc., 
Heidelberg 
GPR55 antibody (#720285) Thermo Fisher Scientific Inc., 
Waltham (MA, USA) 
HO-1 polyclonal antibody 
(#ADI-SPA-895) 
Enzo Life Sciences GmbH, Lörrach 
HO-2 polyclonal antibody 
(ADI-SPA-897) 
Enzo Life Sciences GmbH, Lörrach 
TRPV1 antibody (#PA5-34498) Thermo Fisher Scientific Inc., 
Waltham (MA, USA) 
β-actin monoclonal antibody 
(#A5316) 
Sigma-Aldrich, Taufkirchen 
Secondary antibodies Supplier 
anti-mouse IgG, 
HRP-linked antibody (#7076S) 
Cell Signaling Technology Europe, 
Leiden (The Netherlands) 
anti-rabbit IgG, 
HRP-linked antibody (#7074S) 
Cell Signaling Technology Europe, 
Leiden (The Netherlands) 
Table 12-5: Non-antibody products for Western blot analysis 
Product Supplier 
Prestained SDS-PAGE standard 
(broad range; #161-0318) 
Bio-Rad, Munich 
AmershamTM ProtranTM 0.2 µM NC 
nitrocellulose membrane 
Carl Roth®, Karlsruhe 
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Table 12-6: Gene expression assays and consumables for mRNA analysis 
Gene expression assays Supplier 
HO-1 (Hs01110251_m1; 
FAMTM dye/MGB probe) 
Thermo Fisher Scientific Inc., 
Waltham (MA, USA) 
HO-2 (Hs00157969_m1; 
FAMTM dye/MGB probe) 
Thermo Fisher Scientific Inc., 
Waltham (MA, USA) 
β-Actin (#4352935E; human ACTB 
endogenous control (FAMTM dye/ 
MGB probe, non-primer limited) 
Thermo Fisher Scientific Inc., 
Waltham (MA, USA) 
Consumables Supplier 
AmershamTM ProtranTM 0.2 µM NC 
nitrocellulose membrane 
Carl Roth®, Karlsruhe 
MicroAmpTM fast optical 96-well 
reaction plate, 0.1 mL 
Thermo Fisher Scientific Inc., 
Waltham (MA, USA) 
MicroAmpTM optical adhesive film Thermo Fisher Scientific Inc., 
Waltham (MA, USA) 
Table 12-7: Reagents for RNA interference experiments 
siRNAs Supplier 
HO-1 siRNA (sc-35554) Santa Cruz Biotechnology, Inc., 
Heidelberg 
Negative control siRNA (#1022076) Qiagen, Hilden 
Transfection reagents Supplier 
Lipofectamine® RNAiMAX reagent Thermo Fisher Scientific Inc., 
Waltham (MA, USA) 
Opti-MEM I reduced serum medium Thermo Fisher Scientific Inc., 
Waltham (MA, USA) 
Table 12-8: Technical equipment 
Equipment Supplier 
7500 Fast Real-Time PCR System Thermo Fisher Scientific Inc., 
Waltham (MA, USA) 
AccuriC6TM flow cytometer BD Biosciences, Heidelberg 
Anthos HT II plate reader Anthos Labtec Instruments GmbH, 
Wals-Siezenheim (Austria) 
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Equipment Supplier 
AxioCam ERc 5s digital 
microscope camera  
Carl Zeiss AG, Oberkochen 
Bio-Rad Mini-PROTEAN® 
Tetra Cell System 
Bio-Rad, Munich 
CB 201 CO2 incubator Binder GmbH, Tuttlingen 
Centrifuges (5417R / 5810R) Eppendorf AG, Hamburg 
ChemiDocTM XRS System Bio-Rad, Munich 
HerasafeTM (KS18) 
biological safe cabinet 
Thermo Fisher Scientific Inc., 
Waltham (MA, USA) 
LaminAir HB2448 Heraeus Holding GmbH, Hanau 
Luna-IITM automated cell counter Biozym Scientific GmbH, Hessisch 
Oldendorf 
Megafuge 1.0R Heraeus Holding GmbH, Hanau 
Mr. FrostyTM freezing container Thermo Fisher Scientific Inc., 
Waltham (MA, USA) 
Multi axle rotating mixer RM5-30V CAT Ingenieurbüro, M. Zipperer 
GmbH, Staufen 
Pipettes (variable volumes) Eppendorf AG, Hamburg 
PowerPac (300 / universal) Bio-Rad, Munich 
PrimoVert inverted microscope Carl Zeiss AG, Oberkochen 
SE 250 Mini-Vertical Unit GE Healthcare Europe GmbH, 
Freiburg 
Sonopuls HD Bandelin electronic GmbH & Co KG, 
Berlin 
Thermomixer comfort Eppendorf AG, Hamburg 
Touchmixer VortexGenie1 Scientific Industries, Inc., Bohemia, 
USA 
Trans-Blot SD semi-dry transfer cell Bio-Rad, Munich 
Table 12-9: Software 
Software Supplier 
ACD/ChemSketch Advanced Chemistry Development, 
Inc. (ACD/Labs), Toronto (Canada) 
BD AccuriTM C6 software BD Biosciences, Heidelberg 
GraphPad Prism 6.01 GraphPad Software, Inc, LaJolla 
(CA, USA) 
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Software Supplier 
Microsoft® Office Microsoft Corporation, Redmond 
(WA, USA) 
Quantity One 1-D analysis software Bio-Rad, Munich 
Table 12-10: Consumables 
Product Supplier 
Cell culture well plates 
(6-, 12-, 24-, 96-well; sterile) 
BD Biosciences, Heidelberg 
Centrifuge tubes (15 ml, 50 ml) Sarstedt, Nümbrecht 
Combitips for Eppendorf Multipette®) Eppendorf AG, Hamburg 
Cryopreservation vials (2 ml) Greiner Bio-One GmbH, 
Frickenhausen 
Falcon® cell culture inserts 
(pore size: 8 µM) 
Corning, Wiesbaden, Germany 
Microtest plate (96-well) Sarstedt, Nümbrecht 
Pipette tips Sarstedt, Nümbrecht 
Reaction vials (1.5 ml, 0.5 ml; clear) Sarstedt, Nümbrecht 
Reaction vials (2 ml; clear) Greiner Bio-One GmbH, 
Frickenhausen 
Safe-Lock tubes, amber (0.5 ml, 2 ml) Carl Roth®, Karlsruhe 
Serological pipettes  
(5 ml, 10 ml, 25 ml) 
Sarstedt, Nümbrecht 
Tissue culture flask (75 cm2) Cell+ 
(vented cap) 
Sarstedt, Nümbrecht 
Table 12-11: Composition of buffers and other solutions 
Buffer/Solution Component 
10X TRIS-buffered saline (TBS) 1,000 mM TRIS (ultrapure) 
2,500 mM NaCl 
pH 7.5 
1X TRIS-buffered saline/Tween®20 
(TBS-T) 
100 ml 10X TBS 
900 ml deionized water 
1 ml Tween®20 
10X electrophoresis buffer 250 mM TRIS (ultrapure) 
1,920 mM Glycine 
0.1% (m/v) SDS 
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Buffer/Solution Component 
1X electrophoresis buffer 100 ml 10X electrophoresis buffer 
900 ml deionized water 
5X Stripping-buffer 1,000 mM Glycine 
2500 mM NaCl 
pH 2.5 (adjusted with HCl) 
1X Stripping buffer 50 ml 5X Stripping buffer 
200 ml deionized water 
10% SDS [w/v] 10 g SDS 
100 ml deionized water 
Enhanced chemiluminescence 
solution I (ECL I) 
2.5 mM Luminol 
400 µM p-Coumaric acid 
100 mM TRIS/HCl (pH 8.5) 
Enhanced chemiluminescence 
solution II (ECL II) 
76 mM H2O2 
100 mM TRIS/HCl (pH 8.5) 
ECL detection solution 1 volume ECL I 
1 volume ECL II 
1X Trypsin/EDTA (TE) 5 ml 10X Trypsin/EDTA 
45 ml DPBS 
Sample buffer (for protein isolation) 62.5 mM TRIS/HCl 
2% [v/v] SDS 
10% [v/v] Glycerol 
Blocking solution 5 g Blotting grade blocker 
100 ml deionized water 
Semi-dry transfer buffer 190 mM Glycine 
25 mM TRIS (ultrapure) 
20% (v/v) Methanol 
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Table 12-12: Composition of stacking and separation gel for SDS-PAGE 
Stacking gel; 4% acrylamide concentration Volume 
Aqua ad injectabilia 11.5 ml 
0.5 M TRIS (ultrapure) 4.7 ml 
SDS (10% [w/v]) 188 µl 
Rotiphorese® gel 30 (acrylamide donor) 2.5 ml 
TEMED 19 µl 
APS 95 µl 
Separation gel, 12% acrylamide concentration Volume 
Aqua ad injectabilia 12.7 ml 
1.5 M TRIS (ultrapure) 9.5 ml 
SDS (10% [w/v]) 380 µl 
Rotiphorese® gel 30 (acrylamide donor) 15.2 ml 
TEMED 19 µl 
APS 190 µl 
 
Note: These values serve to produce four gels with a thickness of 1.5 mm each. First, the components 
for the separating gel are mixed and the liquid is filled into the prepared gel chamber. The liquid gel is 
carefully coated with approx. 3 ml of isopropanol. For polymerization (solidification), the gel is 
incubated for 30 min at room temperature, protected from light. After preparation of the stacking gel, 
the isopropanol is removed with filter paper. The separating gel is then coated with the stacking gel. 
After positioning of the pocket comb, the gel is incubated again at room temperature for 30 min, 
protected from light. The prepared gels are individually wrapped in wet paper towels and stored at 
4 °C until use (for a maximum of seven days). 
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12.2 Supplementary information 
  
Figure 12-1: Sequence alignment of HO-1 and HO-2. Alignment was performed using 
protein-protein BLAST. Protein sequences used were NP_002124 (Homo sapiens) for HO-1 and 
P30519 (Homo sapiens) for HO-2 according to the NCBI reference sequences. Compliant amino 
acids are marked in yellow. Heme regulatory motifs (HRM) 1–3 of HO-2 are indicated in the blue 
boxes. The specific amino acid sequence of the “HO-signature” is indicated in the red box. 
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Figure 12-2: NAC and the antioxidant-scavenging glutathione system. N-Acetylcysteine is 
hydrolyzed to the amino acid cysteine and an acetyl group. Cysteine, together with 
glutamic acid and glycine is converted to glutathione in its reduced form (GSH). 
Superoxide anions (O2-) are generated by several oxidases and by mitochondrial 
respiration under hypoxic conditions (not shown here). Superoxide dismutase (SOD) 
converts O2- to hydrogen peroxide. The reactive oxygen species hydrogen peroxide 
may be converted into water by the enzymes catalase (Cat) or glutathione peroxidase 
(GPx). The latter oxidizes GSH to glutathione disulfide (GSSG), which can be 
converted back to GSH by glutathione reductase (GR) in an NADPH-consuming 
process. (Illustration created according to [308–310]) 
Attachment 113 
 
  
Figure 12-3: Principle of immunologic protein detection and horseradish peroxidase 
reaction. Bound to the nitrocellulose membrane, the protein of interest is recognized by the 
corresponding primary antibody. The secondary antibody is directed against the immunoglobulins of 
the species from which the primary antibody originates. A horseradish peroxidase (HRP) is linked to 
the secondary antibody. The ECL solution contains luminol and H2O2, the latter being the substrate 
of the HRP. The H2O2 is reduced to water (H2O) by the HRP. Light is emitted by simultaneous 
oxidation of the luminol. 
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Figure 12-4: Scheme of the construction and function of a flow cytometer. Representation of 
the hydrodynamic focusing of the cells (A). The sample is aspirated by the needle. The sheath fluid 
surrounds the sample flow whereby the cells are separated and focused in the middle of the sample 
stream. The sample is transferred to the flow cell where the single cells pass the laser beams. The 
scattered light is filtered by diverse bandpass filters (e. g. 488/10, light with 478–498 nm can pass the 
filter) and directed towards the detectors (FSC, SSC, FL1–4). The signals are processed and plotted as 
dot plots (e. g. FSC vs. SSC). Fluorescently-labelled cells can be analyzed and plotted as FL-X vs. 
FL-Y. FL-X: fluorescence 1 (e. g. for FITC-Annexin V); FL-Y: fluorescence 2 (e. g. for propidium 
iodide); LP: longpass filter (light with higher wavelength passes, light with lower wavelength is 
reflected); SP: shortpass filter (light with lower wavelength passes, light with higher wavelength is 
reflected); FSC: forward scatter; SSC: side scatter 
Attachment 115 
 
 
Figure 12-5: Effect of CBD on HO-2 mRNA and protein expression in HUASMC. Cells were 
incubated with CBD at 6 µM for the indicated times (A, B). After incubation, cells were analyzed for 
mRNA expression (A) or protein expression (B) of HO-2. Expression values were normalized to 
β-actin. Percent control represents comparison with the corresponding vehicle-treated, time-matched 
group (set as 100%). Vales are means ± SEM of n = 4–5 (A) or n = 3 (B) experiments. *P < 0.05 vs. 
time-matched vehicle control; Student’s two-tailed t test (A, B).  
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